Table Of Content

AUTHOR INDEX (P = Proceedings) AARON, L. see DE ALWIS, D.P BARRY, M. see NAISBITT, D.J quantification of -hydroxytamoxifen, a ADEDOYIN, A., FRYE, R.F., MAURO, BARRY, M.G. see HALIFAX, K.1 genotoxic metabolite of tamoxifen, 296P K. & BRANCH, R.A. Chloroquine BARRY, M.G. see KEWN, S BOURKE, S.]. see DEVEREUX, G modulation of specific metabolizing BARRY, M.G. see PHIBOONBANAKIT, BOUWELS, L.H.R. see VAN KRAAI, enzymes activities: investigation with D DIM selective five drug cocktail, 215 BATTY, A.B. see MORRIS, R.G BOYCE, M. see WARRINGTON, S AIKEN, T.C. see DEVEREUX, G BATTY, K.T. see MAGGS,J. 1 BOYD, A. see JOUBERT, P AJJAN, R.A. see HUSSAIN, F.N BEIJNEN, J.H. see HERBEN, V.M.M BRACCHI, R. HUTCHINGS, A.D., ALINCIC, S. see SCHWAGMEIER, R BEIJNEN, J.H. see HUITEMA, A.D.R WOODS, F.J., HOUGHTON, J., ALLANSON,,J . see SEABER, E.J BEILJNEN, J.H. see MALINGRE, M.M SMAIL, S.A. & ROUTLEDGE, P.A AL-RASHED, S.A., WRIGHT, D.]. & BEIJNEN, J.H. see MEERUM TER Spontaneous reporting of suspected CHRYSTYN, H. The opinions of WOGT, ].M adverse drug reactions by general general practitioners on discharge BEIL, W. see KIRCHNER, G.l practitioners in a UK health region, information, 300P BELL, A. see KHAKOO,S 279P ALVAN, G. see WAKELKAMP, M BELLISSANT, E. & GIUDICELLI, J.-I BRADY, P.A., CHARLETT, A., DOBBS, AMREIN, R. see SALEMING, W. Pharmacokinetic—-pharmacodynamic R.J., PETERSON, D.W., WILKS, M., ANDERSON, B.J., HOLFORD, N.H.G., model relating zabiciprilat plasma WELLER,C . & DOBBS, S.M WOOLLARD, G.A. & CHAN, P.L.S concentrations to brachial and femoral Increased prevalence of Helicobacter pylori Paracetamol plasma and cerebrospinal haemodynamic effects in normotensive seropositivity in sufferers from idiopathic fluid pharmacokinetics in children, 237 volunteers, 383 parkinsonism and their siblings, 302P ANDERSON,C . see CROSS, S.I BELLISSANT, E. see ANNANE, D BRANCH, R.A. Implications of liver ANDERSON, R.A. see ELLIS, G.R BESSARD,G . see STANKE, I disease for regulatory requirements for ANGUS, P. see NAWARATNE, S BEUKEMA, J. see PEETERS, P.A.M drug development, 351 ANNANE, D., BELLISSANT, E., BEUN, A.M. see DE HAAN, G,J BRANCH, R.A. see ADEOYIN, A SEBVI.,L LELSIEEUOR,, O. ., BEUSENBERG, F.B. see HERBEN, BREANT, D. see STANKE, I MATHIEU, B., RAPHAEL, J.C. & V.M.M BRECKENRIDGE, A. see GAJDOS, P. Impaired pressor sensitivity BHAT, G.J. see PEETERS, P.A.M REIDENBERG, M.M to noradrenaline in septic shock patients BIEMBA, G. see PEETERS, P.A.M BRETT, S.E., RITTER, J.M. & with and without impaired adrenal BILLAUD, E.M., GUILLEMAIN, R., CHOWIENCZYK, P.J. Association function reserve, 589 PASCO, F. & CHEVALIER, P between metabolic risk factors and ARMSTRNG, G. see LIPSCOMB, G.R Evidence for a pharmacokinetic exercise blood pressure in health men, ARNOLD, O. see BAILEY, D.G interaction between itraconazole and 288P ARONSON, J.K. Medical Pharmacology at tacrolimus in organ transplant patients, BREYER-PFAFF, U. see SCHABER, G a glance (Book review), 91 771 BRICCA, G. see STANKE, I ASHTON, H. see BIRCH, D BIRCH, D., ASHTON, H., KELLY, P. & BRIEN, J.E. see NAWARATNE, S ASSASSI, K. see KIRCHNER, G.I KAMALI, F. Alcohol and illicit drug use BRINKMANN, K. see BURGER, D.M ATZPODIEN, J. see KIRCHNER, G.I in junior hospital doctors in the north BRINKMAN, K. see HUGEN, P.W.H AUSTIN, C.A. see OATES, A east of England, 278P BROOKS, B. see PROFIT, | AYKROYD, R.G. see WRIGHT, D.J BIRCH, D., WHITE, M., KELLY, P. & BROUWERS, J.R.BJ. see VAN DIJK, KAMALI, F. Alcohol, illicit drug use K.N BABER, N. see TOWARD, T and lifestyle variables in a cohort of first BROWN, AS. see FONTANA, R.]} BABIKER, A.G. see CHURCHILL, D.R year medical students at Newcastle BROWN, O. see RIDGE, S.A BACK, D.J. see EAGLING, V.A University, 301P BROWN, R.R. see FONTANA, R.] BACK, D.J. see HALIFAX, K.1 BIRD, D. see DURSUN, S.M BRUNNER, M., SCHMIEDBERGER, BACK, D.J. see KEWN, S BIRKETT, D.J. se MCMANUS, P A., SCHMID, R., JAGER, D., BACK, D_J. see PHIBOONBANAKIT, D BISHOP, L.P.D., MAGGS, J.L. O’NEILL, PIEGLER, E., EICHLER, H.G. & BACK, D.J. see PROFIT, I P.M. & PARK, B.K. The metabolism of MULLER, M. Direct assessment of BAILEY, D.G., MALCOLM, J., arteflene (Ro 42-1611), an peripheral pharmacokinetics in humans ARNOLD, O. & SPENCE, J.D endoperoxide antimalarial, in rats, 293P comparison between cantharides blister Grapefruit juice drug interactions, 101 BISWAS, P.N. see MARTIN, R.M fluid sampling, in vivo microdialysis and BAK, D.J. see CHURCHILL, D.R BLACK, A.B. see MORRIS, R.G saliva sampling, 425 BAKER, H. see BARDSLEY, H BLASCHKE, T.F. & JAILLON, P BRYSSINE, B. see PALMER, J.1 BALLARIN, E. see LAPORTE, J.-R Discussion session. The solution, 356 BUER, J. see KIRCHNER, G.I BARDSLEY, H., GRISTWOOD, R., BOAKYE, E. see FREUDENTHALER, S BURGER, D.M. see HUGEN, P.W.H BAKER, H., WATSON, N. & BODE-BOGER, S.M., BOGER, R.H., BURGER, D.M., HOETELMANS NIMMO, W. A comparison of the GALLAND, A., TSIKAS, D. & R.M.W., HUGEN, P.W.H., cardiovascular effects of levobupivacaine FROLICH, J.C. L-arginine-induced MULDER, J.W., MEENHORST, P.L., and rac-bupivacaine following vasodilation in healthy humans KOOPMANS, P.P., BRINKMAN, K intravenous administration to healthy pharmacokinetic—pharmacodynamic & HEKSTER, Y.A. Plasma levels of volunteers, 245 relationship, 489 indinavir (IDV) and virological treatment BARDY, A.H. Bias in reporting clinical BOGER, R.H. see BODE-BOGER, S.M failure in HIV-infected patients, 620P trials, 147 BOIKE, S.C. see TENERO, D.M. BURGGRAAF, J., VAN HAARST, A.D., BARNES, S. see RAMSAY, I BOOCOCK, D.J., MAGGS, J.L., WHITE, FOCKENS, P., SCHOEMAKER, BARRINGTON, P. see PALMER, J.1 I.N.H. & PARK, B.K. Identification and H.C., KRAUWINKEL, W,J.J. & © 1998 Blackwell Science Ltd COHEN, A.F. The gastroimtestin with and without apparent liver diseas¢ DOYLiE . opK.m e&n t TIcoNnEfRe,r encR.e s Tfroari nminegm baenrds sceodnatt DDAANRIGmEIaLrE6, k, e rs MH..J]i.n . heEasener td JOfpaoHiilNunrtSes, O Na,n3d6 suMr.rAo gat YRAGO. 11 rch Fp., haertmhLaiA ccMsoA lNocNgoAym,m i tstteudCeise. s,, Ma3sA4s eRsIsiNngO , FFAERERDNE,SI BBBUUUSTTSLL.A EE RR&,,D . SCT. RRA.,. UsRe TeMHS OseeH ERERRTKSTIH,YSA, N, , AH.AS.D..DG.Q¢ . M LEONI DDDDAEAA SVVHE,IA NDLWP.ICO. SR, TF.sLe,.e Ds .KeP.He, A DAK.APO. A OAS,RI OseeL NVLSA5O, ,N ( L.CM .MO.&1R E. ] RV.. EpIeraBMtleiAdAg LiRbDlcIeIo N,nj Osue,nrc Aut mi vNAa.col,or nfclieoEnsnxMttaiMlrclIaiat,ntIi o.n e x&h iibni ts FERDTiR.aNbIcIoAtD po: PALMER, J.L. Populatior CHINire.! K. see MALINGRE, M.M FERRA UCHIN, K. see MEERUM TER FIES, 1 BUTTER, J.J. seeS CHIPPER, H.G VOGT, ].M FISHW BUTTERS, C.]. see WILD, MJ DE BROE, M.1 ee TOHNSON, M.A RSUN, S.M., BIRD, D. & FLINN, J FLANN BCCCYAAEA,LMM PDPBWB‘E EELLLLLL,,, PONJTW... JRs.A- e~R(e&D S ,OW MICLe HL|SI ICTAH,MAS E,F NE RK, M J.! DIDE}E EGMSHH.IMNVAOE.IG.RATO ,ESNN .L, DS JE.MJP.eB .Ac JE sN.T&Ne ,.SJe ,.VB MV EA.AI,N MN .R , .NMPBK .ROIRCRCAAA.TAKD MEJKLI EE&,, RM SA,DK LJE..MPRW . A.B SHEIKpOphir,_nee— n icGi .n M.pt aret ieinstete mse:K ntH-pA!r KeiOsmOius,ntaa nrt 5 FFFFLLOOIOCGNRKLALNIAUII,ZS II IE, MJ. Therapeutic dh CCCCCCCHAHHHHHAVEAAAENVRANNV,ALNNN ALEEEANITRRUPEOT,,.GRNL, ,H., S , KK:.JASP- O..S.. Hss Aeseee eNe BDB OSRSIEATATLRTEDOALSEENYAUSDOK,U,SEE ND, ,L,, LPA.RE AE.IB T .P,J M, D DDDEEE dVSJSeNPA.pTOULeMNONCnA. LdCGN eKI nQD.D,tEIU J VEK.A,SL GN ..TMi n _KOLm..PaD,Bsee nN .?PE, A .END LAS AT6sBeAAe2 SE1PRIPRPLT, VGEE ANR , S F,CH.C A.TMVM <J.I-I L .M. et & EEEAADGSELBOHLAINiCNB,yKGR -.,O p ECeKJoDnVJ,.se .. st A eIePnQ.h HMiUn.Albotl iLEitheIi&Lpyo iFLldnAeV rpEXEtooi TRfxcM2 , yD9EKl 5d.ICLPar .JYu tgP,is2 ,&oD b6nT y 1.8A 5“ CCHHEOVURDEHTU,RSY , RF.APB. RE,& | GORGELS, A.P.» M. Recta I I omcoekirnestic s ebyt neowf vN.i}gg aabbaattrriiln n e MACDERMOT, ]. H ve 6ON2 2P ct nd phI a} rmaocO odynamic EDWwith AA RDSO,PA ,/i mNGp-.li a e cetpst ee yrleM-ctvc AoyGlsuGtmSen,i t neerJ ,. 1 . 62771p yn HOWIENCZYK, P.J BRETT, S.1 DE VRIES, C.S. see VAN DIJK, K.N EGBERTS. A.C.G. seeV AN DEN BEMT, CHOWIENCZYK, PJ FONTANA DEBETS, R.M.¢ ee DE HAAN, G,} ) M_L.A. EGBERTS, A.C.G. see VAN CHOWIENCZYK, P.J. see KNEALI B.] DEBILLON, 1 ce PAWLOTSKY, I ROON. E.N. ELIAS,E . Classification CHRYSTYN, H HAWKSWORTH DEKKER, S., WOUTERSE, A.¢ rity and actiology of liver (;.M STEEGERS, E.A.P., RUSSEI F.G.M CHRYSTYN, H. see Al RASHED, S.A & SMITS, P. The role of endothelium EICHLER, H.G. see BRUNNER,M CHRYSTYN, H. see WRIGHT, DJ on fraction, 624 P CHURCHILL, D.R., PYM, A.S paths ELIASSONE . see RAMSAY, | BABIKER, A.G., BACK, DJ. & — ELLIOTT, HLL. see ROSARIO, M.( WEBER, J.N. Hyj DELEU, D. Levodopa monitoring Dy ELLIOTT, H.L. see UEDA, S ELLIS. G.R., ANDERSON, R.A., itors in patie! vith HIV DESBOEUEF, K., LAPEYRE-MESTRI IACKSON, S.K., LANG, D., M. & MONTASTRUG, J.-L. Risk of FRENNEAUX, M.P. & LEWIS, MJ CCCLLLAAERROKKPE,H. A SD,.] A.. Ts.seJe eLe IWPArWRERONI RNHGTATHVOEB,,N J, S.5M DEVLEICH tRroEimnUteXisnt,tiGan ga. o,ni sFltaI cSmHodWroIr mCaKy, wKi th hoenliicae l ehffefuaerncttc st ifooanfi luvriea,tn da m2io7nx9 iPd© a tiovne stress FRC CLEOPHAS, T.J. see VAN DER AIKEN, T.C., BOURKE, S.J. & ELTHERINGTON, L.G. see MATHER, FRY COCMKECURLOEFNT,,J J.R. see WILKINSON HENDRIjoCse K,of D-Ds.o]t.a loAld verins e pateifefnetcst s woif tha EMMLLI. I. see DRAGQO,I FUN 1.B nild stable asthma, 79 ENGELSMAN, M. see DE HAAN, GJ CCCCCOOOROHOSLRESOLRSNLI,,AON D.S IS,.EP,A.. ,F W. .L. .s Aesee sseNee eRBDeN FO UEAOURWGRTGAASLGRREOIRAD,NATG A,NEFC ,ER,. , & RJ.5 SA DDDEIEVAVSIRIL1 jIOuLEo,ISr Eo,uR rR,a. cBn.TH. ;MP .. S oa rsCiesleev eiSun TiFdciAOanNlNleKy TE ,Aas nNidg Ani,lI5 R J EEZNZSGEPRLITeELI.lLN,a R, tM ioOFHn...HsMJ ..h,A MipMUs eLeET LbIDe,PNt, AGw LeTReE.A nM,.T &, tMA&h K. e DAP.,AR RBKW,A NBG.K, GGGGGAAAAAIIJl! ROBERTS, M.S. Topical penetration o! DDIIEEdTMiZhU.yN dSrKnoC.t peHyrs,reaei c muSiiPodC.ni H nsAede uBeeE RdPteA,o hL yiMdnEGhriR ob,ig te nJ.a1s e,| |. rPtoepmu} eltahtetiirco n r+e psbpheoannrsfmela ucmooektfi€o nl e)Gt Pi cins 5 6ma6al9nad7r ia GGGAEA!! DIJKEMA, A.M. see VAN DIJK, K.N yatients, 553 GI Gl DING, R.W. see PORT, R-E IDA THIS, P. see FABRE, | DINGEMANSE,J . seeS ALEMING,W FABINY, R. see NAWARATNE,S DA MFSEUIRSLRVCAAAZ,R, A ,C .JM..FG.,. MP..,N .D, ADVEI SDO,NU SUFA.C,1 C IS,.SG dispossuiltpihono naamnidd etso,x ici3ty0 5Po l sulphones and FABRE|K-,F. E, RRVEER.Y,O ,E DEC.HA,EN VV,RAE UTZ,FE. ,L SLD.,’I A PTIHECI S,H AUP.D, , POLIMENO, N.C. & PEDRAZZOLI DOBBS. RJ. see BRADY, P.A OLIVE. G. & PONS, G. An approach DOBBS, S.M. see BRADY, P A |. Pltarsomnaid azhoylder oxrya tiom eitnr onaindtaiz- HCV carriers DONNELLY, R. see VEDA, S r dose finding of drugs in infants 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 © | 634 Index sedation by midazolam studied using the GODFREY, C., SWEENEY, K.., HOEFNAGELS, W.H.L. see VAN continual reassessment method, 395 MILLER, K., HAMILTON, R. & KRAAJI, DJ. FARR, S.J. see MATHER, L.I KREMER, J. The population HOETELMANS, R.M.W. see BURGER, FEENSTRA, J., IN’T VELD, B.A., VAN pharmacokinetics of long-term D.M DER LINDEN, P.D., GROBBEE, methotrexate in rheumatoid arthritis, HOETELMANS, R.M.W. see HUGEN, D.E. & STRICKER, B.H.CH. Risk 369 P.W.H factors for mortality in users of GOLDING, J.F. see REID, K HOFFMANN, R. see KIRCHNER, G.I ibopamine7,1 GONG, P.L. see LI, G HOGGARD, P.G. see KEWN,S FERNANDEZ-SALGUERO, P.M. see GONZALEZ, F.J. see RIDGE, S.A HOL, C.W. see TEN HAVE, S.M RIDGE, S.A GRAHAM, E. see PALMER, J.1 HOLFORD, N.H.G. see ANDERSON, FERRAZ, ].G.P. see DA SILVA, C.M.I GRANNEMAN, G.R. see QUELLET, D B,J FIES, T. see PORT, R.I GREENE, D.S. see VACHHARAJANI, HOOY MANS, P.M. see VAN DER KUY, FISHWICK, K. see DEVEREUX, G N.N P.-H.M FLANNERY, B. see KHAKOO, S GRELLIER,L . see KHAKOO, $ HOSKINS, J.M., SHENFIELD, G.M. & FLINN, J. see DURSUN, S.M GREWAL, H.K. see TOWARD, T GROSS, A.S. Relationship between FLOREANI, M. see ORLANDO, R GRIBNAU, F.W.]. see VAN KRAAJL, proguanil metabolic ratio and CYP2C19 FOCKENS, P. see BURGGRAAF, J] D.J.W genotype in a Caucasian population, $99 FOGARI, R., ZOPPI, A., CORRADI, L., HOUGHTON, J. see BRACCHI, A.D GRISTWOOD, R. see BARDSLEY, H LAZZARI, P., MUGELLINI, A. & HOUSE, F. see LUNNON, M.W GROBBEE, D.E. see FEENSTRA, J LUSARDI, P. Comparative effects of HSU, A. see QOUELLET, D GROENEWEGEN, G. see MEERUM lisinopril and losartan on insulin HUGEN, P.W.H. see BURGER, D.M TER WOGT, J.M. GUPTA, V. see sensitivity in the treatment of non HUGEN, P.W.H., BURGER, D.M.., VAN AGTMAEL, M.A. HEKSTER, diabetic hypertensive patients, 467 BRINKMAN, K., KOOPMANS, P.P., Y.A. see BURGER, D.M FONTANA,L ., McNEILLK,. 1 HOETELMANS, R.M.W., GROSS, A.S. Best practice in therapeutic RITTER, J.M. & CHOWIENCZYK, MEENHORST, P.L. & MULDER, drug monitoring, 95 PJ. Inhibitory effects of low-density ].W. Salivary indinavir levels as a method GROSS, A.S. see HOSKINS, J.M lipoprotein on endothelium-dependent to monitor compliance and predict GUILLEMAIN, R. see BILLAUD, E.M relaxation are attenuated by vitamin (¢ plasma levels in HIV positive patients, GUNDERT-REMY, U. see ind A cell permeable superoxide 620P FREUDENTHALER,S dismutase mimetic, 288P HUGHES, S.G. Prescribing for the elderly FONTRA.J.N, DAEVR,IES , T.M.., patient: why do we need to exercise WOOLF, T.F., KNAPP, M.]., HADERSLEV, K.V., SONNE,J ., caution?, 531 BROWN, A.S., KAMINSKY, L.S POULSEN, H.E. & LOFT,S HUITEMA, A.D.R., TIBBEN, M.M., PANG, B.K., FOSTER, N.L., Paracetamol metabolism in patients with KERBUSCH, T., RODENHUIS, S. & BROWN, R.R. & WATKINS, P.B ulcerative colitis, 513 BEIJNEN, J.H. Simultaneous Caffeine based measure of CYP1A2 HALIFAX, K.L. see EAGLING, V.A determination of thioTEPA, activity correlate with oral clearance of HALIFAX, K.L., LINDUP, W.E., cyclophosphamide and some of thei tacrine in patients with Alzheimer’s BARRY, M.G., WILTSHIRE, H.R. & metabolites in plasma using capillary gas disease, 221 BACK, D.J. Binding of the HIV chromotography, 619P FOSTER, N.L. see FONTANAR,J protease inhibitor saquinavir to human HUNG,J . see TAYLOR, M.1 FRANZKE, A. see KIRCHNER, G.I plasma proteins, 291P HUPPERETZ, P.C. see WILKINSON, FREEMANTLE, S.N. see MARTIN, R.M HAMILTON, R. see GODFREY, C LB FRENNEAUX, M.P. see ELLIS, G.R HARRIS, A.L. se MORRIS, R.G HUSSAIN, F.N., AJJAN, R.A., FREUDENTHALER, S., MEINEKE, L., HARRY, F. see SHETTY, H.G.M. MOUSTAFA, M., WEIR, N.W. & SCHREEB, K.-H., BOAKYE, E., HASINOFF, B.B. see SCHAEFER, J.P RILEY, S.A. Mesalazine release from a GUNDERT-REMY, U. & GLEITER, HAWKSWORTH, G.M. & CHRYSTYN, pH dependent formulation: effects of C.H. Influence of urine pH and urinary H. Clinical pharmacy in primary care, omeprazole and lactulose co flow on the renal excretion of 415 administration, 173 memantine, 541 HAYASHI, N., KINOSHITA, H., HUTCHINGS, A.D. see BRACCHI, A.D FROLICH, J.C. see BODE-BOGER, S.M YUKAWA, E. & HIGUCHI, $ HUTCHINGS, A.D. see SHETTY, oe FRYE, R.F. see ADEOYIN, A Pharmacokinetic analysis of H.G.M FUMOLEAU, P. see PALMER, J.I subcutaneous erythropoietin IBANEZ,L . see LAPORTE, J.-R administration with nonlinear mixed ILETT, K.F. seeM AGGS,J. 1 GABRIELSSON,J . see WAKELKAMP, M effect model including endogenous ILSON,B . see TENERO, D.M GAERTNER, HJ. see SCHABER, G production, 11 ILTON, M.K. see TAYLOR, M.1 GAJDOS, P. see ANNANE, D HEFTING, N.R. see SEABER, E.} IN’T VELD, B.A. see FEENSTRA,J GALLAND, A. see BODE-BOGER, S.M. HENDRICK, D.J. see DEVEREUX, G GANDON, J.M. see PATAT, A. HENRY-MOWATT, J.S. see KEWN, S JACKSON, P.R. see OATES, A GANSER, A. see KIRCHNER, G.1 HERBEN, V.M.M., SCHELLENS, JACKSON, S.K. see ELLIS, G.R GARDINER, I. see RAMSAY, | J.H.M., TEN BOKKEL HUININK, JAEHDE, U. see SALEMING, W GERTZ, B,J. see REID, K W.W., ROSING, H., VAN JAGER, D. see BRUNNER, M GIUDICELLI, J-F. see BELLISSANT, E ZOMEREN, D.M., BEUSENBERG, JAILLON, P. see BLASCHKE, T.I GLEITER, C.H. see F.B., ROSS, G. & BEIJNEN, J.H. A JANSEN, R.W.M.M see VAN KRAAIJ, FREUDENTHALER, S new oral dosage form of topotecan DJ.W GLUE, P. see KHAKOO, S$ bioavailability and effect of food co JICK, H. see MYERS, M.W GO, L.H. see VAN KRAAJJ, DJ.W administration, 630P JODRELL, D.1. see ROSARIO, M.C GORGELS, A.P.M. see DE HICKS, A. see LUNNON, M.W JOHNSON, E:S. see WARRINGTON,S . iC h STOPPELAAR, F.M. GRIBNAU, HIGUCHL, S. see HAYASHI, N JOHNSON, M.A., VERPOOTEN, G.A., F.W J. see VAN KRAAIJ, DJ.W HILL, R.G. see LONGMORE, J] DANIEL, M.J., PLUMB, R., MOSS, J., 3-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 635 Index VAN CAESBROECK, D. & DI KINOSHITA,H . see HAYASHI, N eloxicam and piroxicam: a double BROE, M.E. Single dose KIRCHNER, G.I., FRANZKE, A., blind placebo-controlled study, 133 rmacokinetics of lamivudine in BUER,J ., BEMI.,L PR,OBS T IPWORTH, B,J. & CLARK, D.J. Early biects with impaired renal function and KEPPER, F., WITTKE, F., g absorption profile of non-CF(¢ 1¢ effect of haemodialysis, 2 OVERMANN, K., LASSMANN,S tamol via small and large volume MAT JONKERS, R.E. & KOOPMANS, R.P HOFFMANN, R., KIRCHNER, H plastic spacer devices, 45 Vv ihe pharmacokinetics and GANSER, A. & ATZPODIEN,J LIPWORTH, B,J. see KIELY, D.G Pharmacokoifn reectomibicnasnt LIU, G. see REID,K srednisolone (MP) during puls« human interleukin-2 in advanced renal LOCKE, C.S. see QUELLET, D LOFT, S. see HADERSLEV, K.\ il Carcinoma patients tolowl 1 dy in ¢ patients, 618P ibcutancous application, 5 LOHMAN, J.J.H.M. see VAN DER KUY, INKMAN, J.H.G. see SEABER, E.] KIRCHNER,H . see KIRCHNER, G.l P.-H.M JONKMAN, J.H.G. see PEETERS, P.A.M KIVISTO, K.T., KANTOLA, T. & LONGMORE, J., RAZZAQUE, Z.., IRKASKY, D.K PTENERO, D.M NEUVONEN, P_]. Different effects of SHAW, D., DAVENPORT, A.P., JOUBERT, P. & BOYD, A. How does a raconazole on the pharmacokinetics of MAGUIRE, J., PICKARD, J.D., oper vastatin and lov wattle 19 SCHOFIELD, W.N. & HILL, R.G Compoaf trhe ivasosconostrnict or KLOTZ, U. see LI, G JOVIC,R SALEMING, W ts of rizatriptan and sumatriptan in KLOTZ, U. see MORIKE, K n isolated cranial arteries KNAPP, M.]. seeF ONTANA, R.J nunohistological demonstration of KAGER, P.A SCHIPPER, H.G KNEALE, B.J., CHOWIENCZYK, P.]. & nvolvement of 5-HT),-receptors, KAMALI, I e BIRCH, D RITTER M. Actions of propranolol on noradrenalin ediat KAMALI, F. see BIRCH, D YONEN, A.J.M. see VEEN, G.] KAMINSKY, L.S. see FONTANA, R.] Océ ) oO vas ré LUGT, CH.B. see PEETERS, P.A.M KANTOLA, 1 KIVISTO, K.1 of men and women, 281P NNON, M.W., HICKS, A., HOUSI KARBWANG, J. see EZZET, | KOBAYASHI, K. see NAKAJIMA, M F., OLSP.,S PIKEO, NN., S,UMN ER Mc! KASTELEIINNOLST TRENITE, D.G.A KOOPMANS, P.P. see BURGER, D.M M.]., TAYLOR, LW. & WATTS, LS. A A mparison of lamotr KOOPMANS, P.P. see HUGEN, P.W.H rst evaluation in man of escalating Me! KOOPMANS, R. see SCHIPPER, H.G ¢ intravenous doses of glycoprotein MI of an epilepsy 626P KOOPMANS, R.P. see JONKERS, RI IIb/IIla receptor antagonist GR233548, MI KASTELEI]NNOLST TRENITE, D.G.A KOSUGE, K. see KIMURA, M 81P MI DE HAAN, G.] KRAUWINKEL, W.].]. see LUSARDI, P. see FOGARI, R KELLY, P. see BIRCH, D BURGGRAAF, ] LYPNYJ, D. see KHAKOO,S MI KENNA, J.G. see RAMSAY, | KREMER, J. see GODFREY, ¢ KENNA, J. SOMCHIT, N KUROIWA, Y NAKAJIMA, M KERBUSCH, T. see HUITEMA, A.D.R MacCALUM, H. see WILKINSONI,.B MI KERGUERIS, M.1 e PAWLOTSKY, I LA MANNA, C. see DRAGO,| MACDERMOT, J. see CHOUDHURY, KEWN, S., HOGGARD, P.G., HENRY LANG, D. see ELLIS, G.R RP MOWATT, ].S., BARRY, M.G. & LAPEYRE-MESTRE, M. see DESBOEUF, MAGGS, J.L. see PARK, B.K BACK, D.]. Enhanced activation of MAGGS, J.L. see BISHOP, L.P.D K oside analogues in the ce of LAPORTE, J.-R., VIDAL, X., MAGGS, J.L. see BOOCOCK, D.] yxyurea in vitro, 283P BALLARIN, E. & IBANEZ, L. Possibl MAGGS, J.L. see NAISBITT, D.J KHAKOO,S ., GLUE, P., GRELLIER, I MAGGS, J.L., BATTY, K.T., ILETT, K.F., ssociavion between OC ular MI WELLS,B ., BELL, A., DASH,¢ hloramphenicol and aplastic anaemia EDWARDS, G. & PARK, B.K MI MURRAY-LYON, I., LYPNYJ, D the ibsolute risk is very low, 181 Isomerization in human urine of a MI FLANNERY, B., WALTERS, K. & ASSMANN,S . see KIRCHNER, G.1 DUSHEIKO,] G). M. R}i bavirin LAYTON, G. see PECK, R.W 9n19d3opp eroxide drug dihydroartemisin, MI ron alfa b in chr AZZARI, P. see FOGARI, R MI EE, A.F.C. see KIELY, D.G MAGUIRE, J. se LONGMORE, J MI d pharmacodynamic interactions, 563 MALCOLM, J. see BAILEY, D.G LENDERINK, A.W. see VAN DEN MI KHAN, S.Q., STRACHAN, F.I MALIEPAARD, M. see MEERUM TER BEMT, P.M.L.A MI MEGSON,I .L., MAZZEI, F.A WOGT, ].M ENDERINK, A.W. see VAN ROON, NEWBY, D.E., BUTLER, A.R. & MALINGRE, M.M., MEERUM TER E.N WEBB, D.]. A comparisofo nth e effects WOGT, J.M., SCHELLENS, J.H.M LEONARD, J.M. see OQUELLET,D MI of RIG-200, a novel S-nitrosated glyco DUCHIN, K., ROSING, H. & EONE,A . see BUTLER, R Mé BEIJNEN, J.H. Co-administration of ESIEUR, O. see ANNANE,D dorsal Nand veins of healt! yclosporin A interferes with paclitaxel subiects in vivo. 280P UFKENS, H.G.M. see VAN DEN tabolism in humans, 626P Mi KIELY, D.G., LEE, A.F.« BEMT, P.M.L.A MALLARD, N. see WARRINGTON, S$ Mi STRUTHERS, A.D. & LIPWORTH WIS, M.]. see ELLIS, G.R MANN, R.D. Prescription-event B.J. Nitric oxide: an important rote mm , G., GONG, P.L., QIJ.U, ZE,NG, I 1onitoring — recent progress and future 1c Maintenance Of systemic and D. & KLOTZ, U. Stereoselective steady 1orizons, 195 pulmonary vascular tone in man, 263 state disposition and action of MANN, R.D. see MARTIN, R.M Mi KIMURA, M., UMEMURA, K.., propafenone in Chinese subjects, 441 MARINO, A. see DRAGO, I M KOSUGE, K., NISHIMOTO, M LINDNER, J. se MCMANUS, P MARINO, V. see DRAGO, I OHASHI, K. & NAKASHIMA, M LINDUP, W.E. see HALIFAX, K.I MARLEY, J. see MCMANUS, P Attenuation by ACE inhibitor drugs of LINDUP, W.E. see SHAH, LA MARTIN, D.E. see TENERO, D.M z-adrenoceptor sensitivity in human LIPSCOMB, G.R., WALLIS, N.., MARTIN, R.M., BISWAS, P.N., vessels: possible differences related to ARMSTRONG, G. & REES, W.D.W FREEMANTLE, S.N., PEARCE, G.1 drug lipophilicity, 599 Gastrointestinal tolerability of & MANN, R.D. Age and sex 636 © 1998 Biackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 Index distribution of suspected adverse drug MOSS, J. see JOHNSON, M.A OOSTELBOS, M.C.].M. see VEEN, G.] reactions to newly marketed drugs in MOUSTAFA, M. see HUSSAIN, F.N OOSTERHUIS, B. see PEETERS, P.A.M neral practice in England: analysis of MOYOU, R.S. see PEETERS, P.A.M ORLANDO, R., FLOREANI, M., 48 cohort studies, 505 MUCKLOW, J.C. A manual of adverse PADRINI, R. & PALATINI, P MATHER, L.E., WOODHOUSE, A., drug interactions (Book review), 275 Determination of inulin clearance by WARD, M.E., FARR, S.]., MUGELLINI, A. see FOGARI, R bolus intravenous injection in healthy RUBSAMEN, R.A. & MULDER, J.W. see BURGER, D.M subjects and ascitic patients: equivalenc ELTHERINGTON, L.G. Pulmonary MULDER, J.W. see HUGEN, P.W.H of systemic and renal clearances a ninistration of acrosolised fentany! MULL, R. see EZZET, I glomerular filtration markers, 605 nacokinetic analysiosf systemic MULLER, M. see BRUNNER, M ORME, M. Drugs and human lactation delivery, 37 MURRAY, G.D. The design and analysis of Book review), 91 MATHIEU, B. see ANNANE,D sequential clinical trials (Book review), OSBORNE, C.M. see PEETERS, P.A.M MAURO, K. see ADEOYIN, A $13 OTTO,C ., PARHOFER, K.G., MAZZEI, F.A. see KHAN, S.Q MURRAY, L. Sample size tables for clinical RITTER, M.M., RICHTER, W.O. & McCULLOCH, P.G. see SHAH, LA studies (Book review), 616 SCHWANDT, P. Effects of acipimox McGRATH, J.C. Use of models to study MURRAY-LYON, I. see KHAKOO, S$ on haemorpheology and plasma vascular aspects of heart failure, 360 MUSCARA, M.N. see DA SILVA, C.M.I lipoprote Ins in patients with mixed McKENNA, W.]. Genetic aspects of heart MYERS, M.W. & JICK, H. Terfenadinc hyperlipoproteinaemia, 473 failure, 36 ind 2r isrek of acutsheai ilicvetr disea» se, De2 51 OUELLET, D., HSU, A., QIANJ,. , McKILLOP,D . see WILD, M_] LOCKE, C.S., EASON, C,] McLEOD, H.L. see RIDGE, S.A NACKE, A. see REICHEL, (¢ CAVANAUGH, J.H., LEONARD McMANUS, P., MARLEY, J., BIRKETT, NAISBITT, D.J. see WILLIAMS, D.P ].M. & GRANNEMAN, G.R. Effect of D.J. & LINDNER, J., Compliance with NAISBITT, D.J., VILAR, J., WILKINS, ritonavir on the pharmacokinetics of restrictions on the subsidized use of E.G.L., BARRY, M. PIRMOHAMED, ethinyl oestradiol in healthy female proton pump inhibitors in Australia, 409 M. & PARK, B.K. Plasma cysteine volunteers, 111 ES.RA McMheUarRt RAfaiYlu,re J(.C HRFe)c ent3 60 trials in chronic diemfpilciiceantciyo nsi n foHr IVs ulipnhfaecmteetdh apzaotlieen ts OUWDEJL.SW, L.H.R. see VAN KRAAIT], McNEILL, K.L. see FONTANA,| hypersensitivity, 285P OVERMANN, K. see KIRCHNER, G.1 NAISBITT, D.J., WILLIAMS, D.P., MEENHORST, P.L. see BURGER, D.M PIRMOHAMED, M. & PARK, B.K MEENHORST, P.L. see HUGEN, P.W.H Amodiaquine-induced neutrophil PADRINI, R. see ORLANDO, R MEERUM TER WOGT, J|.M. see apoptosis, 292P PALATINI, P. se ORLANDO, R MALINGRE, M.M NAISBITT, D.J., WILLIAMS, D.P., PALMER, J.L. see DE ALWIS, D.P MEERUM TER WOGT, J.M., BEIJNEN, MAGGS, J.L., PIRMOHAMED, M. & PALMER, J.L., BARRINGTON, P. & J.H., TEN BOKKEL HUININK, PARK, B.K. Metabolism-dependent O'CONNOR-SEMMES, R. Safety W.W., ROSING, H., VAN neutrophil toxicity of amodiaquine: a tolerability and pharmacokinetics of the MEERUM TER WOGT, J.M., BEIJNEN, comparison with related antimalarial NK, receptor antagonist GR205171 in JJ.. TEN BOKKEL HUININK, W.W drugs, 291P healthy male volunteers, 298P MALIEPAARD, M., TIBBEN, M., NAKAJIMA, M., KOBAYASHI, K., PALMER, J.L., FUMOLEAU, P., WELBANK, H., GROENEWEGEN, SHIMADA, N., TOKUDOME, S., BRYSSINE, B., DIEMUNSCH, P., G. & SCHELLENS, J.H.M. Phase I and YAMAMOTO, T. & KUROIWA, Y SCHOEFFLER, P., SPRAGGS,C . & pharmacologic study of SPI-77, a new Involvement of CYP1A2 in mexiletine GRAHAM, E. Preliminary aF., liposomal encapsulated formulation of metabolism, 55 pharmacokinetcs of the NK, receptor MEGSON, LL. see KHAN, $.Q NAKASHIMA, M. see KIMURA, M antagonist GR205171 in patients with MEINEKE, I. see FREUDENTHALER, S$ NAWARATNE, S., BRIEN, J.1 chemtherapy-induced or post operative MERKUS, F.W.H.M. see VAN DER SEEMAN, E., FABINY, R., nausea and vomiting, 297P KUY, P.-H.M ZALCBERG, J., COSOLO, W.., PANFILOV,V . see UEDA, S$ MIGET, N. see PATAT, A ANGUS, P. & MORGAN, DJ PARHOFER, K.G. see OTTO, ¢ MIKUS, G. see MORIKE, K Relationships among liver and kidney PARK, B.K. see BISHOP, L.P.D MILLER, A.K. see TENERO, D.M volumes, lean body mass and drug PARK, B.K. see BOOCOCK, D.] MILLER, K. see GODFREY, ¢ clearance, 447 PARK, B.K. see GILL, H_] MINTO,C . & SCHNIDER, T. Expanding NEUVONEN, P.]. see KIVISTO, K.1 PARK, B.K. see MAGGS, J.1 clinical applications of population NEWBY, D.E. see KHAN, S.Q PARK, B.K. see NAISBITT, DJ pharmacodynamic modelling, 321 NIEMEYER, M.G. see TEN HAVE, S.M PARK, B.K. see WILLIAMS, D.P MISSO, N.L.A. see TAYLOR, MI NIMMO, W. see BARDSLEY, H PARK, B.K., O'NEILL, P.M., MAGGS MONTASTRUC, J.-L. see DESBOEUF, NISHIMOTO, M. see KIMURA, M J.L. & PIRMOHAMED, M. Safety K assessment of peroxide antimalarials MORGAN, D.]. see NAWARATNE, S$ (’CONNOR-SEMMES, R.. see clinical and chemical perspectives, 52 >1 MORIKE, K., PLATTEN, H.P., MIKUS, PALMER, J.1 PARK, B.K. see PIRMOHAMED, M G. & KLOTZ, VU. Variability in the O’KANE, K. Streetwise drugwise (Book PARK, B.K. Prediction of drug-induced future frequency of cytochrome P450—2D6 review), 615 hepatotoxicity, 357 (CYP2D6) deficiency, 87 O'NEILL, P.M. see PARK, B.K PATAT, A., TROCHERIE, S., MIGET MORRIS, A.D. see BUTLER, R O’NEILL, P.M. see BISHOP, L.P.D N., ENSLEN, M., GANDON, J.M. & MORRIS, A.D. see UEDA,S OATES, A., JACKSON, P.R., AUSTIN, ROSENZWEIG, P. Effects of a slow MORRIS, R.G., BLACK, A.B., HARRIS, C.A. & CHANNER, K:.S. A new release formulation of caffeine on EEG A.L., BATTY, A.B. & SALLUSTIO, regimen for start warfarin therapy in out pscyhomotor and cognitive functions 1n B.C. Lamotngine and therapeutic drug patients, 157 sleep-deprived health volunteers, 285P monitoring: retrospective survey OHASHI, K. see KIMURA, M PAWLOTSKY, F., THOMAS, A., following the introduction of a routine OLIVE, G. see FABRE, I KERGUERIS, M.F., DEBILLON, 7 service, 54 OLSSON, P. see LUNNON, M.W & ROZE, J.C. Constant rate infusion of 133-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 637 Index RADEMAKER, M.V. see DE HAAN, G.] ROTBLAT, F. What information does the SCH new OSA chedule, 163 RAMSAY, L., BARNES, S., GARDINER, lator presently require before SCHI PEARCE, G.L. see MARTIN, R.M I., ELIASSONE . & KENNA, J.G a new drug to be used in FI PECK, R.W. see SEABER, E.] Idenuficauion by immunopre¢ ipitatiion of patients with liver disease? 352 SCH’ PECK, R.W., WOOTTON, R., WIGGS nove! halothane-induced protem YUTLEDGE, P.A. see BRACCHI, A.D S R., LAYTON, G. & POSNER, J. Eff tigens recognized by antibodies from ROUTLEDGE, P.A. see SHETTY paticnts with halothane hepatitis, 303P H.G.M RAMSAY, L.A. see SOMCHIT, N LOUTLEDGE,R .A., SHETTY, H.G.M SCH RAPHAEL, J.¢ ee ANNANE, D WHITE, J.P. & COLLINP.S C,as e SCIB PEDRAZZOLI ee DA SILVA, C.M.1 RAWLINS, M.D. What does a doctor nc therapeutics Wartarin SEAI PEETERS, P.A.M., BEUKEMA, ] to Know about a new drug Defore It 1s stance and inefhicacy in a man with D OOSTERHUIS, B., SMEETS rrent thromboemt F.W.M., MOYOU, R-S., THIETCHI Oaggut lant—associatea pprrii apism 343 ROWKINS, S. se WARRINGTON, S F., OSBORNE, C.M., THUMA, P.I BHAT, G.]., BIEMBA, G RAZZAQUE, Z. see LONGMORE, } ROZE, J.C. see PAWLOTSKY,I SHAKANKALE, G.M., JONKMAN REES, W.D.W. see LIPSCOMBG,.R RUBSAMEN, R.A. seeM ATHER, L.I 7¢ }.H.G. & LUGT, CH.B REIBALDI, A. see DRAGO,| RUSSEL, F.G.M. see DEKKER, S SEBI REICHEL, C., SKODRA, T., NACKE, SEEN A., SPENGLER, U. & SESS SALEMING, W., JAEHDE, | SAUERBRUCH, T. The lignocaine SHA SCHONING,H . & SIEGERT, W. O tabolite (MEGX) liver function test PENG, Y SCHAEFERJ,. P thylation of etoposide: a potential ind P-450 induction in humans, 535 PETERSON, D.W. see BRADY, P.A of drug interactions, 627P REID, K., SCIBERRAS, D.G., GERTZ PHIBOONBANAKIT, D., BARRY SALEMING, W., JOVIC, R., AMREIN B.J., REINHARDT, R.R., LIU, G M.G. & BACK, D.J. Q R. & DINGEMANSE, J. Tolerability, GOLDING, |.F. & STOTT, J.R.R 1acokKinectics ana 94P Comparison of a neurokinin 1codynamics of combined PICKARD, J.D LONGMORI | 98,298, and scopo obemide and diazepam in healthy with placebo in the prevention of PICKKERS, P DE HOON, ].N.].M ts, 628P PIECHAUD, J-I FABRE, I ouon-induced nauseai n man, 282P SALLUSTIO, B.C. see MORRIS, R.G REIDENBERG, M.M. & PIEGLER, I BRUNNER, M SAPONE, A. see RIDGE, S.A PIKE, N LUNNON, M.W BRECKENRIDGE, A. Summary SAUERBRUCH, T. see REICHEL, ¢ SHA PIRMOHAMED, M. & PARK, K. Arc SCHABER, G., STEVENS,L. , SHA REIDENBURG, M. Cl GAERTNER, H,J., DIETZ, K. & SHI BREYER-PFAFF, U. Pharmacokinet PIRMOHAMED, M. see PARK, B.K REIMCHE, L. seeS CHAEFER, J.P f clozapine and its metabolites in SHI PIRMOHAMED, M. see GILL, H.J REINHARDT, R.R. see REID, K hiatric patients: plasma protein SHI PIRMOHAMED, M. see NAISBITT, D_] REY, E. see FABRE, I nding and renal clearance, 453 PIRMOHAMED, M. see WILLIAMS, D.P RICHELL, R. see TOWARD, 7 J HAEFER, J.P., TAM, Y., HASINOFF, SHI PLATTEN, H.P. see MORIKE, K RICHTER, W.O. see OTTO, ¢ B.B., TAWFIK, S., PENG, Y.., PLUMB, R.. see JOHNSON, M.A RIDGE, S.A., SLUDDEN, J., BROWN REIMCHE, L. & CAMPBELL, N.R.¢ SHI O., ROBERTSON, L., WEI, X POGGI, I ¢ SPEIRS, C.J I ous sulfate interacts with captopril, SAPONE, A., FERNANDEZ POLIMENON,. C. see DA SILVA, C.M.1 PONS, G. see FABRE, |} SALGUERO, P.M., GONZALEZ, F.} SCHARER,K . see PORT, R.I VREKEN, P., VAN KUILENBURG SCHEININ, H. see WAKELKAMP, M OOLE-WILSON, P. Fi A.B.P., VAN GENNIP, A.H. & SCHELLENS, }.H.M. see HER BEN, SHI McLEOD, H.L. Dihydropyrimidine V.M.M SHY PORT, R.E., DING, R.W., FIES, T. & hydrogenase pharmacogenctics 1n SCHELLENS, J.H.M. see MALINGRE, SIEC SCHARER, K. Predicting the (Caucasiat pa 15 M.M SIE] AILEY, S.A. see HUSSAIN, F.N SCHELLENS, ].H.M. see MEERUM TER SIM LITTER, J.M. see BRETT, S.I WOGT, J.M ina 1, 46 LITTER, J.M. see FONTANA, I 7, HIPPER, H.G., BUTTER, J.]., SK¢ POSNER, J. see PECK, R.W RITTER, J.M. see KNEALE, B.] KAGER, P.A., VAN BOXTEL, C_]. & SLL POULSEN, H.1 e HADERSLEVK,.\ LITTER, M.M. see OTTO,¢ KOOPMANS, R. The effect of SM/ PROBST-KEPPER, M. see KIRCHNER LOBERTS, M.S. see CROSS, S.I 1etidine and dose increase on SMI G.I ROBERTSON,L . see RIDGE, S.A oncentrofa altbeindoaznol e-sulphoxide SMI PROFIT, L., BROOKS, B., WILLIAMS LODENHUIS, S. see HUITEMA, A.D.R iealthy subjects, 618P SMI D.P. & BACK, D.J. Modulation of P LOLFE, L. seeW ARRINGTON, S$ SCHMID, R. see BRUNNER, M rycoprotein function in humiat ROOTS, |. see PUCHLER,K SCHMIEDBERGER, A. see BRUNNER, SMI peripheral mononuclear cells by LOSARIO, M.C., THOMSON, A.H M SMI saq . , r 295! ) JODRELL, D.1., SHARP, C.A. & SCHNIDER, T. see MINTO,¢ SM’ PUCHLER, K., SIEERAKOWSKI, B. & ELLIOTT, H.L. Population SCHOEFFLER, P. see PALMER, J.1 ROOTS, I. Single dose and steady stat« phar 1acoking tics of gentamicin 1n S CHOEMAKER, H.C. see SOI pharmacokineticos f temocapril and patients with cancer, 229 BURGGRAAF, ] SO! temocaprilat in young and elderly ROSENZWEIG, P. see PATAT,A SCHOFIELD, W.N. see LONGMORE, J hypertensiv patients, 363 ROSING,H . see HER BEN, V.M.M Lr CHOLZE, J. & STAPFF, M. Start of PYM, A.S. see CHURCHILL, D.R ROSING, H. see MALINGRE, M.M herapy with the angiotensin II ROSING, H. see MEERUM TER itagonist losartan after immediate QIAN, J. see OUELLET, D WOGT, J.M switch from pretreatment with an ACI QIU, J. see LI, G ROSS,G . see HERBEN, V.M.M hibitor. 169 638 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 Index SCHONING,H . see SALEMING,W SONNE, J. see HADERSLEV, K.V TENERO, D.M., MARTIN, D.E., SCHREEB, K.-H. see SOUSA, S.S. see DA SILVA, C.M.I MILLER, A.K., ILSON, B., BOIKE, FREUDENTHALER,S SPEIRS, C.J., WAGNIART, F., POGGI, S.C., ZARIFFA, N. & JORKASKY, Ss CHWAGMEIER, R., ALINCIC, S. & L. Perindopril postmarketing D.K. Effect of age and gender on the STRIEBEL, H.W. Midazolam surveillance: a twelve-month study in 47 pharmacokinetics of eprosartan, 267 pharmacokinetics following intravenous 351 hypertensive patients, 63 rER BERG, J.W.M. see VAN DER KUY, and buccal administration, 203 SPENCE, J.D. see BAILEY, D.G P.-H.M SCHWANDT,P . see OTTO,( ¢ SPENGLER,U . see REICHEL, ¢ THIETCHE, F. see PEETERS, P.A.M Sy CIBERRAS, D.G. see REID,K SPRAGGS,C . see PALMER, J.1 THOMAS, A. see PAWLOTSKY, SEABER,E .]., PECK, R.W., SMITH, STANKE,F ., DEVILLIER,P , BREANT, THOMPSON, PJ. see TAYLOR, M.1 D.A., ALLANJ.S, OHEFNTI,NG , D., CHEVANON, O., SESSA, (¢ THOMSON, A.H. see ROSARIO, M.¢ N.R., VAN LIER, J.J., SOLLIE, F.A.E., BRICCA, G. & BESSARD, G THUMA, P.E. see PEETERS, P.A.M WEMER, J. & JONKMAN, J.H.G Frusemide inhibits angiotensin II rIBBEN, M. se MEERUM TER WOGT, The absolute bioavail lit and effect of induced contraction on human vascular J.M rIBBEN, M.M. see HUITEMA, A.D.R rood on the pnar macoKkIine smooth muscle, 571 zolmitriptan in healthy volunteers, 433 STAPFF, M. see SCHOLZE,J TINER, R. see DOYLE, K SEBILLE,V . see ANNANE,D STAPPERS, ].L.M. see DI TINGLE, M.D. see GILL, H.] SEEMAN,E . seeN AWARATNE, S STOPPELAAR, F.M PFOKUDOME, S. see NAKAJIMA, M SESSA,C . see STANKE, | STEEDS, R.P. & CHANNER, K.S TOLL, P.J.M.M. see VEEN, G.] SHAH,I .A., LINDUP, W.E. & POWARD, T., RICHELL, R., GREWAL, Recent advances in the management of McCULLOCH, P.G. Freundlich and unstable angina and non-Q-wave H.K., BYE, C. & BABER, N Langmuir isot} herms as descriptors of myocardial infarction, 335 Applanation tonometry: reproducibility inC adsorptiotno acti STEEGERS, E.A.P. see DEKKER,S and repeatability of pulse wave forms and charcoal, 299P STEVENS, I. see SCHABER, G pulse wave velocity using the SHAH,I .A., LINDUP, W.E. & sphygmocor system, 286P STOLK, L.M.L. see DE STOPPELAAR, McCULLOCH, P.G. The effect of POWARD, T., RICHELL,R ., GREWAL, F.M proteoni tnh e adsorptioonf mitomycin H.K., BYE, C. & BABER, N STOTT, DJ. Drug therapy in old age C to activated charcoal, 300P Applanation tonometry: variation in Book review), 413 SHAKANKALE, G.M. see PEETERS, pulse wave forms as a result of STOTT, J.R.R. see REID, K P.A.M sumulation, 287P SHARP, C.A. see ROSARIO, M.¢ STRACHAN, F.E. see KHAN, S.Q PROCHERIE,S . see PATAT, A SHAW, D. see LONGMORE, ] STRICKER, B.H.CH. see FEENSTRA,J PSIKAS, D. see BODE-BOGER, S.M SHENFIELD, G.M. Drug development for STRIEBEL, H.W. see SCHWAGMEIER, FUCKER, G.T. Alteration of drug R women (Book review), 521 aisposiuon 1n live! impairment, 9D5 STRUTHERS, A.D. see BUTLER,R SHENFIELD, G.M. see HOSKINS, ].M STRUTHERS, A.D. see KIELY, D.G UEDA, S., DONNELLY,R ., PANFILOV SHENFIELD, G.M. Therapeutic drug STRUTHERS, A.D. see YEE, K.M V., MORRIS, A.D. & ELLIOTT, H.1 monitoring beyond 2000, 93 SUMNER, M.,]. see LUNNON, M.W Lacidipine: effects on vascular pressor rr, SHETTY, H.G.M. see ROUTLEDGE, SWART, M. see MEERUM TER WOGT, responses throughout the dosage interval R.A }.M in normotensive subjects, 127 SHETTY, H.G.M.,B USS, D.« SWEENEY, K. see GODFREY, ( UMEMURA, K. see KIMURA, M HARRY,F ., HUTCHINGS, A.D. & ROUTLEDGE, P.A. The effect of oral rAM, Y. see SCHAEFER, J.P VACHHARAJANI, N.N., SHYU, W.¢ cholestyramine on the pharmacokinetics PANG, B.K. see FONTANA, RJ SMITH, R.A. & GREENE, D.S. The of warfarin enantiomers, 290P effects of age and gender on the SHIMADA, N. see NAKAJIMA, M PASCO, F. see BILLAUD, E.M pharmacokinetics of irbesartan, 612 SHYU, W.C. see VACHHARAJANI, N.N TAWFIK, S. see SCHAEFER, J.P VAN AGTMAEL, M.A., GUPTA, V. & SIEGERT, W. see SALEMING, W PAYLOR, LW. see LUNNON, M.W PTAYLOR, M.L., ILTON, M.K., MISSO, VAN BOXTEL, C.J. Grapefruit juice SIERAKOWSKI, B. see PUCHLER, K increases the bioavailability of TER SIMONS, K.A. see VAN DEN BEMT, N.L.A., WATKID.NN.,S HU,NG, J. & artemether, 629P P.M.L.A THOMPSON, P.J. The effect of aspirin VAN BORTEL, L.M.A.B. see DE HOON, SKODRA, T. see REICHEL, ¢ on thrombin stimulated platelet adhesion j.N.J.M SLUDDEN,,J . see RIDGE, S.A receptor expression and the role of VAN BOXTEL, C.]. see SCHIPPER, H.G SMAIL, S.A. see BRACCHI, A.D neutrophils, 139 VAN BOXTEL, C.J. see VAN AGTMAEL, SMEETS, F.W.M. see PEETERS, P.A.M LLINGEN, O., SWARTM,. , M.A yx1de SMITH, D.A. see SEABER, E.] DUCHIN, K. & SCHELLENS, ].H.M VAN CAESBROECK, D. see JOHNSON, SMITH, R.A. see VACHHARAJANI, Co-administration of cyclosporin A M.A N.N CsA) enables oral therapy with VAN DEN BEMT, P.M.L.A., EGBERTS, IER, SMITS, P. see DE HOON, J.N.J.M paclitaxel, 624P A.C.G., LENDERINK, A.W., SMITS, P. see DEKKER, S N BOKKEL HUININK, W.W. see VERZIJL, J.M., SIMONS, K.A., VAN SMYTH, A. The paediatric lung (Book HERBEN, V.M.M DER POL, W.S.C.J.M. & LEUFKENS, review), 615 N BOKKEL HUININK, W.W. see H.G.M. Reporting of adverse drug SOLLIE, F.A.E. see SEABER, E,] MEERUM TER WOGT, J.M reactions in hospital 1 comparison of SOMCHIT, N., RAMSAY, L.A., N HAVE, S.M., CLEOPHAS, T.]., doctors, nurses and patients as sources of KENNA, J.G. & CALDWELL,J HOL, C.W., VAN DER MEULEN, J., reports, 619P Glucuronidation mediates hepatic NIEMEYER, M.G. & DE PLANQUE, VAN DEN BERG, P.B. see VAN DIJK, protein adduct formation from B.A. A randomized placebo-controlled K.N diclofenac, but not ibuprofen, in rats: a study of loop-diuretics in patients with VAN DER KUY, P.-H.M., LOHMAN, ACI potential mechanism of hepatotoxicity, essential hypertension, the BUFUI JJ.H.M., HOOYMANS, P.M., TER 304P clinical study report, 628P BERG, ].W.M. & MERKUS, 33-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 639 Index F.W.H.M. Pharmacokineticosf VAN THOOR, C.]. see WILKINSON, WEMER,, J. see SEABER, E.J 1.B WHITE, I.N.H. see BOOCOCK, D.] ihydroergotamine, 623P VAN ZOMEREND.,M . see HERBEN WHITE, J.P. see ROUTLEDGE, R.A VAN DER LINDEP.ND., s ee V.M.M WHITE, M. see BIRCH, D FEENSTRA, | VAUZELLE-KERVROEDAN, F. see WIGGS, R. see PECK, R.W VAN DER MEULEN, J. see TEN HAVI FABRE,I WILD, M.J., BUTTERS, C.J]. & a-adr S.M VEEN, G.]., OOSTELBOS, M.C.].M., McKILLOP, D. Determination of the a-hy VAN DER MEULEN, J., VAN DER TOLL, P.J.M.M. & LOONEN, A.J.M hepatic cytochrome P450 ACI SLUIJS, J.P., CLEOPHAT.S],. & Effect of blood collection tubes o1 Zymes INnvoi. ved . in ZOi. mitriptan ana ACI ZWINDERMAN, A.H. Replacemen ricyclic antidepressantb lood levels \-desmethy! zolmitriptan metabolism i All ACE-inhibitors by All-receptor 631P 29QP 7 VERME]], T.A.C. see EDELBROEK, WILKINS, E.G.L. see NAISBITT, D.] Acet P.M WILKINSON, I.B., HUPPERETZ, P.¢ Adar 11a ) ( ell ictaboh VERPOOTEN, G.A. see JOHNSON VAN THOOR, C.J., MacCALUM, H Adre VAN DER POL, W.S.C.J.M. see VAN M.A COCKCROFPT, J.R. & WEBB, D_J Adve DEN BEMT, P.M.L.A VERZIJL, ].M. see VAN DEN BEMT A 1yperglycaemia reduces central Advi VAN DER SLUIJS, J.P VAN DER P.M.L.A terial pressure in healthy subjects, 289P Advi MEULEN, ] VERZIJL, J.M. seeV AN ROON, E.N WILKS, M. see BRADY, P.A A fric VAN DIJK, K.N., DE VRIES, C.S., VAN VIDAL, X. see LAPORTE, J.-R WILLIAMS, D.P. see PROFIT, | Age. DEN BERG, P.B., DIIKEMA, A.M VILAR,J . see NAISBITT, D.] WILLIAMS, D.P. see NAISBITT, D_J Agre BROUWERS, J.R.B.J. & DE JONG VREKEN, P. see RIDGE, S.A WILLIAMS, D.P., NAISBITT, DJ Airv PIRMOHAMED, M. & PARK, B.K Albe VAN DEN BERG, L.T.W WAGNIART, F., see SPEIRS, C.J Co! WAKELKAMP, M., ALVAN, G., Clozapine induces tinoenu-tdreoppheinld enatp optosis AAllzcl« SCHEININ, H. & GABRIELSSON, J] Lys: implicatiofnosr Aml The influence of dr nt y rh VAN GENNIP, A.H. see RIDGE, S.A ¢ ulocytosis, 282P VAN HAARST, A.D. see BURGGRAAF, } WILLIAMS, K.M. see CAMPBELL, T.] Ana WILTSHIRE, H.R. see HALIFAX, K.I Ang VAN KRAAIJ, D.J.W., JANSEN WALLIS, N. see LIPSCOMB, G.R R.W.M.M, GO, I.H., BOUWELS WALTERS, K. see KHAKOO, $ WITTKE, F. see KIRCHNER, G.I Ang WOODHOUSE, A. see MATHER, L.I Ang L.H.R., HOEFNAGELS, W.H.1I WARD, ME. seeM ATHERL,. I WOODS, F.]. see BRACCHI, A.D Ang GRIBNAU, F.W,]. A rando1 WARRINGTON, S., BOYCE, M WOOLF, T.F. see FONTANA, R.] Ang oO ROLFE, L., CLARKE, A WOOLLARD, G.A. see MALLARD, N. & JOHNSON, E.S ANDERSON, B.] Ant Higher availability elegil WOOTTON, R. see PECK, R.W Ant VAN KRAAIJ], DJ.W., JANSEN Zydis™ thar Deprenyl™ for n WOUTERSE, A.C. see DEKKER, S Ant R.W.M.M., BOUWELS, L.H.R. & HOEFNAGELS, W.H.L. Post ssor response to oral tyramin WRIGHTD,. J. see AL-RASHED, S.A Ant »84P WRIGHT, D.J., AYKROYD, R.G. & Ant Od pr re reductions 1n eciderly CHRYSTYN H. Rating clinical Ant WARRINGTON, S., BOYCE, M., ROLFE, L., CLARKE, A nacy interventionbsy clinical Ant MALLARD, N., ROWKINS, S. & s: which health professionals should An vith Ww 625P led?, 27 Ap! VAN KRAAI], DJ.W., JANSEN JOHNSON, E:S. Are the metaboliteosf ded?, 278P Ap R.W.M.M., DE GIER, J.J Art GRIBNAU, F.&W H.OEFJNA.GEL S AMAMOTO, T. see NAKAJIMA,M W.H.L. Prescription patteorfn dsiu t yra , 297P YEE, K.M. & STRUTHERS, A.D Art Lx } ommunity-awe WATKINS, D.N. see TAYLOR, M.1 Endogenous angiotensin II and Ast atients, 403 WATKINS, P.B. see FONTANA, R.] roreceptor dysfunction: a comparative Ast VAN KUILENBURG, A.B.P WATSON,N . see BARDSLEY,H dy of losartan and enalapril in man, At RIDGE, S.A WATTS, LS. seeL UNNON, M.W VAN LIER, J.}. seeS EABERE,. ] WEBB, D.]. see KHAN, S.Q YUKAWA, E. see HAYASHI, N VAN ROON, E.N., EGBERTS, A.C.G WEBB, D.]. see WILKINSON, 1.B VERZIJL, J.M. & LENDERINK, A.W WEBER, J.N. see CHURCHILL, D.R Ba Patterns of switching and stopping init WEI, X. see RIDGE, S.A ZALCBERG, J. see NAWARATNE,S $ Be ZARIFFA, N. see TENERO, D.M WEIR, N.W. see HUSSAIN, F.N Be HAART) in a cohofo Durtcht HI V WELBANK, H. see MEERUM TER ZENG, F.-D. see LI, G Bi sCTOpOSIO VC patients, 62 P WOGT, ].M ZOPPI, A. see FOGARI,R Bi VAN TELLINGEN, O. see MEERUM WELLER,C . see BRADY, P.A ZWINDERMAN, A.H. see VAN DER Bl TER WOGT, J.M WELLS,B . see KHAKOO,S MEULEN, J Bl Bc Be Be Bc Be Be Be 640 © 1998 Blackwell Science Ltd Br| Clin Pharmacol, 45, 633-640 SUBJECT INDEX his index was compiled from the keywords x-adrenoc eptor, 599 Book review: Streetwise Drugwise—a Drug cocktail, 2-hydroxytamoxif layman’s guide 615 Drug developer, 352 ACE inhibitor, 363 Book review: The design and analysis of Drug development, 351 ACE inhibitors, 630P sequential 413 Drug disposition, 355 All receptor antagonists, 630P Book review: The paediatric lun Drug input rate, 479 Acetominophen, 237 Buccal, 203 Drug interaction, 1, 101, 111, 377, 563 Acetylcholine, 51 BUFUL clinical study, 628P Drug interactions, 627P Adaptation, 133 Bufuralol, 55, 295P Drug metabolism, 151 Adrenal function, 589 Drug regulator, 352 Adverse drug reaction monitoring, 63 ~ >YP2C19, 499 Drug safety monitoring, 195 Adverse drug reactions, 279P, 505, 619P CYP2D6, 55, 295P Drug utilization, 409 9p Adverse effects, 255 CYP3A4, 101, 535 Drug-induced hepatotoxicity, 357 African children, 629P Caffeine, 221, 285P Drugs and the liver, 351 267, 505, 612 Calcitonin gene related peptide, 621P Duration of action, 12 Agranulocytosis, 282P Calcium antagonists, 58 Airway responsi “ness, /9 Cancer, 229 Efffeecctt comNpnaarrttmmeenntt <7 27 x yw Albendazole-sulphoxide, 618P ( uptopril, 169, 377 Elderly, 363, 531, 625P Alcohol, 278P, 301P Cardiac catheterisation, 395 Enalapril 583 Alzheimer’s disease, 221 Cardiovascular function, 245 Enantuiomers, 79, 290P, 441, 627P Ambulatory blood pressure monitoring, 169 cDNA expressed microsomes, 55 Endogenous production, 11 Amodiaquine, 292P Central arterial pressure, 289P Endothelial function, 279P, 51° Analysis, 547 Cerebrospinal fluid, 237 Endothelium, 489 Angiotensin, 599 Charcoal, activated, 299P, 300P Epilepsy, 547, 626P Angiotensin II, 571, 583 Chloramphenicol, 181 Epoctin B, 11 Angiotensin II receptor antagonist, 267 Chloroquine, 215 Eprosartan, 267 Angiotensin antagonism, 169 Cholestyramine, 290P Erythropoictin, 11 Angiotensin converting enzyme inhibitor, Cimetidine, 618P Ethinyloestradiol, 599 Cisplatin, 625P Ethoxyresorufin 55 Anti-epileptic drugs, 185 Clinical Pharmacology studies, 347 Etoposide, 627P Antiarrhythmic drugs, 307 Clinical interpretation, 95 Exercise blood pressure, 288P Anticoagulation, 157 Clinical panels, 278P Anticonvulsant, 547 Clinical pharmacy, 278P, 415 Fentanyl, 37 Antihistamines, 251 Clinical trials, 147 Fibrinogen, 473 Antimalarial, 293P Clozapine, 282P, 453 1orourach, a| Antipyrine clearance, 44 Clozapine-N-oxide, 453 Fluvastatin, 49 Antiretroviral therapy, 621P Cognitive function, Food. 83. $33. 630 Aplastic anaemia Complex formation, 377 Forearm vasculaature, 281P Applanation tonometry, 286P, 287P Compliance, 620P Freundlich isotherm, 299P Arteflene, 293P Compliance with subsidy restrictions, 409 Frusemide, 479, 571, 624P, 625P Artemether, 553, 629P Computer simulations, 321 Furafylline, 55 Artemisinin, 521 Concentration-effect modelling, 383 Aspirin, 139 Conjunctival instillation, 272 GPIlb-IIla, 139 uve Asthma, 79 Constipation, 255 GR205171, 297P Atrial fibrillation, 15 Continuous rate infusion, 163 GR233548, 281P Covariate analysis, 117 Gastrointestinal haemorrhage, 88 Creatinine clearance, 447 Gender, 83, 267, 505, 612 4-arteether, 629P Cyclophosphamide, 619P Gene-dose effect, 499 Baroreceptor, 583 Cyc losporin A, 624P, 626P General practice, 505 Beclomethasone, 207 Cysteine deficiency, 285P General pracutuioners, 279, 300P Benflumeto, 553 Cytochrome P450, 55, 176, 221, 290P, 535 Genetic aspects, 361 Bias, 147 Cytochrome P450—2D6 87 Genotype, 499 Bioavailability, 37, 433, 553, 629P, 630P Gentamicin, 229 Blood collection tubes, 631P Delayed release mesalazine, 173 Glucuronidation, 111 Blood donors, 176 Deprenyl, 284P Glycoprotein IIb/IIIa receptor antagonist, Bolus i.v. injection, 605 Diabetes mellitus, type II, 630P 281P Book review: A ma ual of adverse drug Diazepam, 628P Glycosalicylate, 29 interactions, 275 Diclofenac, 304P GR205171, 298P Book review: Drug therapy in old age, 413 Didanosine, 283P Grapefruit juice, 101, 629P Book review: Drug development for Dihydroartemesinin, 293P women 520 Dihydroergotamine, 623P HCV-RNA, 563 Book review: Drugs and human lactation 91 Dihydropyrimidine, 151 HIV infected patients, 285P, 620P Book review: Medical pharmacology at a Dihydropyrimidine dehydrogenase, 1, 151 HIV positive patients, 621P glanc e 91 Discharge information, 300P HIV protease inhibitors, 291P Book review: Sample size tables for clinical Diuretics, 403 HIV-1 infection, 518 trials 616 Dose-response curve, 589 HIV-protease inhibitors, 295P 3-640 © 1998 Blackwell Science Ltd 641 Percutaneous, 29 Perindopr}i l, 63 Loop diuretics P 628 Pernpheral resistance, 489 Hand vein 280P LLoosvaarstt atin1,, 1694,9 467. 583 PPe roxideaeb le anstuimpaelraorixaildse. d5i2s1m utase, 288P Low dos¢ MEGxX test, 535 P 1 icodynamics. 101, 23 321, 441 LLuonwg Iclisvietryy , lip4o5p rotein, 288P Pp o+e79p,i de56m3i.o l2o9g9y,, 62129P5, 628P ibrosis, 618P , ogenct > , KINCuCs, 5, 21, 37, 49. 83. 101 63, 203, 271. 93 26 2 290P 17P, 298P. 363, 433, 441. 541 63 Meloxicam. 133 , ‘ ) O¢ vig&iPl anc6e2, 2P, 16952 3P 6? Pp 628P H lent drug deliven 13 p 33 Metabolix Msk factors, 288P rotein binding, 291P. 453 Pp 39 P. orphisr 15 - , 69. on5 53 netics, 11, 11 , 229, ndial blood pressure, 625P P rkecting surveillance6,3 . 505 P umpsia, 622P AAwW itaA NA DpI re infants, 163 P puon sequence analysis. 255 Pr nbing, 531 Py; pOuNon peavtetnetr nsm on4i0t3o ring. 195 905 Motion sickness. 282P Pressor re sponse, 297P , 345 > care, 415 tomvcir IQQp Pric icrapy. 409 Pri iil. 499 N -< nhetyiclozepine,. 453 Pro; fenone, 441 NONMEM 16 Pp, DT nolol, 281P Py ise inhibitors, 111.518 Prot 300P p*r oton catiponu mabopia a si,n hi1b4i 14t ors. 409 Pulmonary 1dmunistration, 3 P onary circulation. 263 lors 19 3p co TO + () S99 ( oO +9 2 00, 280P ) oO Octo R vacaine 245 K oO 14 i ferences 441 i 1, Ki ous id 7 OPA/n-acetyl-] V 627P ‘ Carance, 453 nun 8 Ren 1 pu x01P R function, 21 2"5 Onpoadeny y tasc 965 R Ethics( ¢ ommiuttees, 34 ) eprazok ) I< Odialysis, 88 Ondansetro R itoid arthritis, 369 ion 624P OOrxaild atciovnet rascterpestsi v: 279P | RIRi fa \ ci1n,, 56533 5 Risk factors, 71 P glycoprotein, 295P Rautonay ] P-selectin, 139 PK PD modelling, 383 S(-) enantiome2r4,5 Paclitaxel 624P, 626P SPI ¢ 25P Paracetamol, 237 $25,513 Safety, 298P Parkinsonism 302P Safety assessment. 521 Salbutamol. 45 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 64/ 643 © 1998

ebook img

British Journal of Clinical Pharmacology 1998: Vol 46 Index PDF

13 Pages·1998·5.3 MB·English
by  
#periodicals #sim_microfilm #pub_british-journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview British Journal of Clinical Pharmacology 1998: Vol 46 Index

AUTHOR INDEX (P = Proceedings) AARON, L. see DE ALWIS, D.P BARRY, M. see NAISBITT, D.J quantification of -hydroxytamoxifen, a ADEDOYIN, A., FRYE, R.F., MAURO, BARRY, M.G. see HALIFAX, K.1 genotoxic metabolite of tamoxifen, 296P K. & BRANCH, R.A. Chloroquine BARRY, M.G. see KEWN, S BOURKE, S.]. see DEVEREUX, G modulation of specific metabolizing BARRY, M.G. see PHIBOONBANAKIT, BOUWELS, L.H.R. see VAN KRAAI, enzymes activities: investigation with D DIM selective five drug cocktail, 215 BATTY, A.B. see MORRIS, R.G BOYCE, M. see WARRINGTON, S AIKEN, T.C. see DEVEREUX, G BATTY, K.T. see MAGGS,J. 1 BOYD, A. see JOUBERT, P AJJAN, R.A. see HUSSAIN, F.N BEIJNEN, J.H. see HERBEN, V.M.M BRACCHI, R. HUTCHINGS, A.D., ALINCIC, S. see SCHWAGMEIER, R BEIJNEN, J.H. see HUITEMA, A.D.R WOODS, F.J., HOUGHTON, J., ALLANSON,,J . see SEABER, E.J BEILJNEN, J.H. see MALINGRE, M.M SMAIL, S.A. & ROUTLEDGE, P.A AL-RASHED, S.A., WRIGHT, D.]. & BEIJNEN, J.H. see MEERUM TER Spontaneous reporting of suspected CHRYSTYN, H. The opinions of WOGT, ].M adverse drug reactions by general general practitioners on discharge BEIL, W. see KIRCHNER, G.l practitioners in a UK health region, information, 300P BELL, A. see KHAKOO,S 279P ALVAN, G. see WAKELKAMP, M BELLISSANT, E. & GIUDICELLI, J.-I BRADY, P.A., CHARLETT, A., DOBBS, AMREIN, R. see SALEMING, W. Pharmacokinetic—-pharmacodynamic R.J., PETERSON, D.W., WILKS, M., ANDERSON, B.J., HOLFORD, N.H.G., model relating zabiciprilat plasma WELLER,C . & DOBBS, S.M WOOLLARD, G.A. & CHAN, P.L.S concentrations to brachial and femoral Increased prevalence of Helicobacter pylori Paracetamol plasma and cerebrospinal haemodynamic effects in normotensive seropositivity in sufferers from idiopathic fluid pharmacokinetics in children, 237 volunteers, 383 parkinsonism and their siblings, 302P ANDERSON,C . see CROSS, S.I BELLISSANT, E. see ANNANE, D BRANCH, R.A. Implications of liver ANDERSON, R.A. see ELLIS, G.R BESSARD,G . see STANKE, I disease for regulatory requirements for ANGUS, P. see NAWARATNE, S BEUKEMA, J. see PEETERS, P.A.M drug development, 351 ANNANE, D., BELLISSANT, E., BEUN, A.M. see DE HAAN, G,J BRANCH, R.A. see ADEOYIN, A SEBVI.,L LELSIEEUOR,, O. ., BEUSENBERG, F.B. see HERBEN, BREANT, D. see STANKE, I MATHIEU, B., RAPHAEL, J.C. & V.M.M BRECKENRIDGE, A. see GAJDOS, P. Impaired pressor sensitivity BHAT, G.J. see PEETERS, P.A.M REIDENBERG, M.M to noradrenaline in septic shock patients BIEMBA, G. see PEETERS, P.A.M BRETT, S.E., RITTER, J.M. & with and without impaired adrenal BILLAUD, E.M., GUILLEMAIN, R., CHOWIENCZYK, P.J. Association function reserve, 589 PASCO, F. & CHEVALIER, P between metabolic risk factors and ARMSTRNG, G. see LIPSCOMB, G.R Evidence for a pharmacokinetic exercise blood pressure in health men, ARNOLD, O. see BAILEY, D.G interaction between itraconazole and 288P ARONSON, J.K. Medical Pharmacology at tacrolimus in organ transplant patients, BREYER-PFAFF, U. see SCHABER, G a glance (Book review), 91 771 BRICCA, G. see STANKE, I ASHTON, H. see BIRCH, D BIRCH, D., ASHTON, H., KELLY, P. & BRIEN, J.E. see NAWARATNE, S ASSASSI, K. see KIRCHNER, G.I KAMALI, F. Alcohol and illicit drug use BRINKMANN, K. see BURGER, D.M ATZPODIEN, J. see KIRCHNER, G.I in junior hospital doctors in the north BRINKMAN, K. see HUGEN, P.W.H AUSTIN, C.A. see OATES, A east of England, 278P BROOKS, B. see PROFIT, | AYKROYD, R.G. see WRIGHT, D.J BIRCH, D., WHITE, M., KELLY, P. & BROUWERS, J.R.BJ. see VAN DIJK, KAMALI, F. Alcohol, illicit drug use K.N BABER, N. see TOWARD, T and lifestyle variables in a cohort of first BROWN, AS. see FONTANA, R.]} BABIKER, A.G. see CHURCHILL, D.R year medical students at Newcastle BROWN, O. see RIDGE, S.A BACK, D.J. see EAGLING, V.A University, 301P BROWN, R.R. see FONTANA, R.] BACK, D.J. see HALIFAX, K.1 BIRD, D. see DURSUN, S.M BRUNNER, M., SCHMIEDBERGER, BACK, D.J. see KEWN, S BIRKETT, D.J. se MCMANUS, P A., SCHMID, R., JAGER, D., BACK, D_J. see PHIBOONBANAKIT, D BISHOP, L.P.D., MAGGS, J.L. O’NEILL, PIEGLER, E., EICHLER, H.G. & BACK, D.J. see PROFIT, I P.M. & PARK, B.K. The metabolism of MULLER, M. Direct assessment of BAILEY, D.G., MALCOLM, J., arteflene (Ro 42-1611), an peripheral pharmacokinetics in humans ARNOLD, O. & SPENCE, J.D endoperoxide antimalarial, in rats, 293P comparison between cantharides blister Grapefruit juice drug interactions, 101 BISWAS, P.N. see MARTIN, R.M fluid sampling, in vivo microdialysis and BAK, D.J. see CHURCHILL, D.R BLACK, A.B. see MORRIS, R.G saliva sampling, 425 BAKER, H. see BARDSLEY, H BLASCHKE, T.F. & JAILLON, P BRYSSINE, B. see PALMER, J.1 BALLARIN, E. see LAPORTE, J.-R Discussion session. The solution, 356 BUER, J. see KIRCHNER, G.I BARDSLEY, H., GRISTWOOD, R., BOAKYE, E. see FREUDENTHALER, S BURGER, D.M. see HUGEN, P.W.H BAKER, H., WATSON, N. & BODE-BOGER, S.M., BOGER, R.H., BURGER, D.M., HOETELMANS NIMMO, W. A comparison of the GALLAND, A., TSIKAS, D. & R.M.W., HUGEN, P.W.H., cardiovascular effects of levobupivacaine FROLICH, J.C. L-arginine-induced MULDER, J.W., MEENHORST, P.L., and rac-bupivacaine following vasodilation in healthy humans KOOPMANS, P.P., BRINKMAN, K intravenous administration to healthy pharmacokinetic—pharmacodynamic & HEKSTER, Y.A. Plasma levels of volunteers, 245 relationship, 489 indinavir (IDV) and virological treatment BARDY, A.H. Bias in reporting clinical BOGER, R.H. see BODE-BOGER, S.M failure in HIV-infected patients, 620P trials, 147 BOIKE, S.C. see TENERO, D.M. BURGGRAAF, J., VAN HAARST, A.D., BARNES, S. see RAMSAY, I BOOCOCK, D.J., MAGGS, J.L., WHITE, FOCKENS, P., SCHOEMAKER, BARRINGTON, P. see PALMER, J.1 I.N.H. & PARK, B.K. Identification and H.C., KRAUWINKEL, W,J.J. & © 1998 Blackwell Science Ltd COHEN, A.F. The gastroimtestin with and without apparent liver diseas¢ DOYLiE . opK.m e&n t TIcoNnEfRe,r encR.e s Tfroari nminegm baenrds sceodnatt DDAANRIGmEIaLrE6, k, e rs MH..J]i.n . heEasener td JOfpaoHiilNunrtSes, O Na,n3d6 suMr.rAo gat YRAGO. 11 rch Fp., haertmhLaiA ccMsoA lNocNgoAym,m i tstteudCeise. s,, Ma3sA4s eRsIsiNngO , FFAERERDNE,SI BBBUUUSTTSLL.A EE RR&,,D . SCT. RRA.,. UsRe TeMHS OseeH ERERRTKSTIH,YSA, N, , AH.AS.D..DG.Q¢ . M LEONI DDDDAEAA SVVHE,IA NDLWP.ICO. SR, TF.sLe,.e Ds .KeP.He, A DAK.APO. A OAS,RI OseeL NVLSA5O, ,N ( L.CM .MO.&1R E. ] RV.. EpIeraBMtleiAdAg LiRbDlcIeIo N,nj Osue,nrc Aut mi vNAa.col,or nfclieoEnsnxMttaiMlrclIaiat,ntIi o.n e x&h iibni ts FERDTiR.aNbIcIoAtD po: PALMER, J.L. Populatior CHINire.! K. see MALINGRE, M.M FERRA UCHIN, K. see MEERUM TER FIES, 1 BUTTER, J.J. seeS CHIPPER, H.G VOGT, ].M FISHW BUTTERS, C.]. see WILD, MJ DE BROE, M.1 ee TOHNSON, M.A RSUN, S.M., BIRD, D. & FLINN, J FLANN BCCCYAAEA,LMM PDPBWB‘E EELLLLLL,,, PONJTW... JRs.A- e~R(e&D S ,OW MICLe HL|SI ICTAH,MAS E,F NE RK, M J.! DIDE}E EGMSHH.IMNVAOE.IG.RATO ,ESNN .L, DS JE.MJP.eB .Ac JE sN.T&Ne ,.SJe ,.VB MV EA.AI,N MN .R , .NMPBK .ROIRCRCAAA.TAKD MEJKLI EE&,, RM SA,DK LJE..MPRW . A.B SHEIKpOphir,_nee— n icGi .n M.pt aret ieinstete mse:K ntH-pA!r KeiOsmOius,ntaa nrt 5 FFFFLLOOIOCGNRKLALNIAUII,ZS II IE, MJ. Therapeutic dh CCCCCCCHAHHHHHAVEAAAENVRANNV,ALNNN ALEEEANITRRUPEOT,,.GRNL, ,H., S , KK:.JASP- O..S.. Hss Aeseee eNe BDB OSRSIEATATLRTEDOALSEENYAUSDOK,U,SEE ND, ,L,, LPA.RE AE.IB T .P,J M, D DDDEEE dVSJSeNPA.pTOULeMNONCnA. LdCGN eKI nQD.D,tEIU J VEK.A,SL GN ..TMi n _KOLm..PaD,Bsee nN .?PE, A .END LAS AT6sBeAAe2 SE1PRIPRPLT, VGEE ANR , S F,CH.C A.TMVM <J.I-I L .M. et & EEEAADGSELBOHLAINiCNB,yKGR -.,O p ECeKJoDnVJ,.se .. st A eIePnQ.h HMiUn.Albotl iLEitheIi&Lpyo iFLldnAeV rpEXEtooi TRfxcM2 , yD9EKl 5d.ICLPar .JYu tgP,is2 ,&oD b6nT y 1.8A 5“ CCHHEOVURDEHTU,RSY , RF.APB. RE,& | GORGELS, A.P.» M. Recta I I omcoekirnestic s ebyt neowf vN.i}gg aabbaattrriiln n e MACDERMOT, ]. H ve 6ON2 2P ct nd phI a} rmaocO odynamic EDWwith AA RDSO,PA ,/i mNGp-.li a e cetpst ee yrleM-ctvc AoyGlsuGtmSen,i t neerJ ,. 1 . 62771p yn HOWIENCZYK, P.J BRETT, S.1 DE VRIES, C.S. see VAN DIJK, K.N EGBERTS. A.C.G. seeV AN DEN BEMT, CHOWIENCZYK, PJ FONTANA DEBETS, R.M.¢ ee DE HAAN, G,} ) M_L.A. EGBERTS, A.C.G. see VAN CHOWIENCZYK, P.J. see KNEALI B.] DEBILLON, 1 ce PAWLOTSKY, I ROON. E.N. ELIAS,E . Classification CHRYSTYN, H HAWKSWORTH DEKKER, S., WOUTERSE, A.¢ rity and actiology of liver (;.M STEEGERS, E.A.P., RUSSEI F.G.M CHRYSTYN, H. see Al RASHED, S.A & SMITS, P. The role of endothelium EICHLER, H.G. see BRUNNER,M CHRYSTYN, H. see WRIGHT, DJ on fraction, 624 P CHURCHILL, D.R., PYM, A.S paths ELIASSONE . see RAMSAY, | BABIKER, A.G., BACK, DJ. & — ELLIOTT, HLL. see ROSARIO, M.( WEBER, J.N. Hyj DELEU, D. Levodopa monitoring Dy ELLIOTT, H.L. see UEDA, S ELLIS. G.R., ANDERSON, R.A., itors in patie! vith HIV DESBOEUEF, K., LAPEYRE-MESTRI IACKSON, S.K., LANG, D., M. & MONTASTRUG, J.-L. Risk of FRENNEAUX, M.P. & LEWIS, MJ CCCLLLAAERROKKPE,H. A SD,.] A.. Ts.seJe eLe IWPArWRERONI RNHGTATHVOEB,,N J, S.5M DEVLEICH tRroEimnUteXisnt,tiGan ga. o,ni sFltaI cSmHodWroIr mCaKy, wKi th hoenliicae l ehffefuaerncttc st ifooanfi luvriea,tn da m2io7nx9 iPd© a tiovne stress FRC CLEOPHAS, T.J. see VAN DER AIKEN, T.C., BOURKE, S.J. & ELTHERINGTON, L.G. see MATHER, FRY COCMKECURLOEFNT,,J J.R. see WILKINSON HENDRIjoCse K,of D-Ds.o]t.a loAld verins e pateifefnetcst s woif tha EMMLLI. I. see DRAGQO,I FUN 1.B nild stable asthma, 79 ENGELSMAN, M. see DE HAAN, GJ CCCCCOOOROHOSLRESOLRSNLI,,AON D.S IS,.EP,A.. ,F W. .L. .s Aesee sseNee eRBDeN FO UEAOURWGRTGAASLGRREOIRAD,NATG A,NEFC ,ER,. , & RJ.5 SA DDDEIEVAVSIRIL1 jIOuLEo,ISr Eo,uR rR,a. cBn.TH. ;MP .. S oa rsCiesleev eiSun TiFdciAOanNlNleKy TE ,Aas nNidg Ani,lI5 R J EEZNZSGEPRLITeELI.lLN,a R, tM ioOFHn...HsMJ ..h,A MipMUs eLeET LbIDe,PNt, AGw LeTReE.A nM,.T &, tMA&h K. e DAP.,AR RBKW,A NBG.K, GGGGGAAAAAIIJl! ROBERTS, M.S. Topical penetration o! DDIIEEdTMiZhU.yN dSrKnoC.t peHyrs,reaei c muSiiPodC.ni H nsAede uBeeE RdPteA,o hL yiMdnEGhriR ob,ig te nJ.a1s e,| |. rPtoepmu} eltahtetiirco n r+e psbpheoannrsfmela ucmooektfi€o nl e)Gt Pi cins 5 6ma6al9nad7r ia GGGAEA!! DIJKEMA, A.M. see VAN DIJK, K.N yatients, 553 GI Gl DING, R.W. see PORT, R-E IDA THIS, P. see FABRE, | DINGEMANSE,J . seeS ALEMING,W FABINY, R. see NAWARATNE,S DA MFSEUIRSLRVCAAAZ,R, A ,C .JM..FG.,. MP..,N .D, ADVEI SDO,NU SUFA.C,1 C IS,.SG dispossuiltpihono naamnidd etso,x ici3ty0 5Po l sulphones and FABRE|K-,F. E, RRVEER.Y,O ,E DEC.HA,EN VV,RAE UTZ,FE. ,L SLD.,’I A PTIHECI S,H AUP.D, , POLIMENO, N.C. & PEDRAZZOLI DOBBS. RJ. see BRADY, P.A OLIVE. G. & PONS, G. An approach DOBBS, S.M. see BRADY, P A |. Pltarsomnaid azhoylder oxrya tiom eitnr onaindtaiz- HCV carriers DONNELLY, R. see VEDA, S r dose finding of drugs in infants 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 © | 634 Index sedation by midazolam studied using the GODFREY, C., SWEENEY, K.., HOEFNAGELS, W.H.L. see VAN continual reassessment method, 395 MILLER, K., HAMILTON, R. & KRAAJI, DJ. FARR, S.J. see MATHER, L.I KREMER, J. The population HOETELMANS, R.M.W. see BURGER, FEENSTRA, J., IN’T VELD, B.A., VAN pharmacokinetics of long-term D.M DER LINDEN, P.D., GROBBEE, methotrexate in rheumatoid arthritis, HOETELMANS, R.M.W. see HUGEN, D.E. & STRICKER, B.H.CH. Risk 369 P.W.H factors for mortality in users of GOLDING, J.F. see REID, K HOFFMANN, R. see KIRCHNER, G.I ibopamine7,1 GONG, P.L. see LI, G HOGGARD, P.G. see KEWN,S FERNANDEZ-SALGUERO, P.M. see GONZALEZ, F.J. see RIDGE, S.A HOL, C.W. see TEN HAVE, S.M RIDGE, S.A GRAHAM, E. see PALMER, J.1 HOLFORD, N.H.G. see ANDERSON, FERRAZ, ].G.P. see DA SILVA, C.M.I GRANNEMAN, G.R. see QUELLET, D B,J FIES, T. see PORT, R.I GREENE, D.S. see VACHHARAJANI, HOOY MANS, P.M. see VAN DER KUY, FISHWICK, K. see DEVEREUX, G N.N P.-H.M FLANNERY, B. see KHAKOO, S GRELLIER,L . see KHAKOO, $ HOSKINS, J.M., SHENFIELD, G.M. & FLINN, J. see DURSUN, S.M GREWAL, H.K. see TOWARD, T GROSS, A.S. Relationship between FLOREANI, M. see ORLANDO, R GRIBNAU, F.W.]. see VAN KRAAJL, proguanil metabolic ratio and CYP2C19 FOCKENS, P. see BURGGRAAF, J] D.J.W genotype in a Caucasian population, $99 FOGARI, R., ZOPPI, A., CORRADI, L., HOUGHTON, J. see BRACCHI, A.D GRISTWOOD, R. see BARDSLEY, H LAZZARI, P., MUGELLINI, A. & HOUSE, F. see LUNNON, M.W GROBBEE, D.E. see FEENSTRA, J LUSARDI, P. Comparative effects of HSU, A. see QOUELLET, D GROENEWEGEN, G. see MEERUM lisinopril and losartan on insulin HUGEN, P.W.H. see BURGER, D.M TER WOGT, J.M. GUPTA, V. see sensitivity in the treatment of non HUGEN, P.W.H., BURGER, D.M.., VAN AGTMAEL, M.A. HEKSTER, diabetic hypertensive patients, 467 BRINKMAN, K., KOOPMANS, P.P., Y.A. see BURGER, D.M FONTANA,L ., McNEILLK,. 1 HOETELMANS, R.M.W., GROSS, A.S. Best practice in therapeutic RITTER, J.M. & CHOWIENCZYK, MEENHORST, P.L. & MULDER, drug monitoring, 95 PJ. Inhibitory effects of low-density ].W. Salivary indinavir levels as a method GROSS, A.S. see HOSKINS, J.M lipoprotein on endothelium-dependent to monitor compliance and predict GUILLEMAIN, R. see BILLAUD, E.M relaxation are attenuated by vitamin (¢ plasma levels in HIV positive patients, GUNDERT-REMY, U. see ind A cell permeable superoxide 620P FREUDENTHALER,S dismutase mimetic, 288P HUGHES, S.G. Prescribing for the elderly FONTRA.J.N, DAEVR,IES , T.M.., patient: why do we need to exercise WOOLF, T.F., KNAPP, M.]., HADERSLEV, K.V., SONNE,J ., caution?, 531 BROWN, A.S., KAMINSKY, L.S POULSEN, H.E. & LOFT,S HUITEMA, A.D.R., TIBBEN, M.M., PANG, B.K., FOSTER, N.L., Paracetamol metabolism in patients with KERBUSCH, T., RODENHUIS, S. & BROWN, R.R. & WATKINS, P.B ulcerative colitis, 513 BEIJNEN, J.H. Simultaneous Caffeine based measure of CYP1A2 HALIFAX, K.L. see EAGLING, V.A determination of thioTEPA, activity correlate with oral clearance of HALIFAX, K.L., LINDUP, W.E., cyclophosphamide and some of thei tacrine in patients with Alzheimer’s BARRY, M.G., WILTSHIRE, H.R. & metabolites in plasma using capillary gas disease, 221 BACK, D.J. Binding of the HIV chromotography, 619P FOSTER, N.L. see FONTANAR,J protease inhibitor saquinavir to human HUNG,J . see TAYLOR, M.1 FRANZKE, A. see KIRCHNER, G.I plasma proteins, 291P HUPPERETZ, P.C. see WILKINSON, FREEMANTLE, S.N. see MARTIN, R.M HAMILTON, R. see GODFREY, C LB FRENNEAUX, M.P. see ELLIS, G.R HARRIS, A.L. se MORRIS, R.G HUSSAIN, F.N., AJJAN, R.A., FREUDENTHALER, S., MEINEKE, L., HARRY, F. see SHETTY, H.G.M. MOUSTAFA, M., WEIR, N.W. & SCHREEB, K.-H., BOAKYE, E., HASINOFF, B.B. see SCHAEFER, J.P RILEY, S.A. Mesalazine release from a GUNDERT-REMY, U. & GLEITER, HAWKSWORTH, G.M. & CHRYSTYN, pH dependent formulation: effects of C.H. Influence of urine pH and urinary H. Clinical pharmacy in primary care, omeprazole and lactulose co flow on the renal excretion of 415 administration, 173 memantine, 541 HAYASHI, N., KINOSHITA, H., HUTCHINGS, A.D. see BRACCHI, A.D FROLICH, J.C. see BODE-BOGER, S.M YUKAWA, E. & HIGUCHI, $ HUTCHINGS, A.D. see SHETTY, oe FRYE, R.F. see ADEOYIN, A Pharmacokinetic analysis of H.G.M FUMOLEAU, P. see PALMER, J.I subcutaneous erythropoietin IBANEZ,L . see LAPORTE, J.-R administration with nonlinear mixed ILETT, K.F. seeM AGGS,J. 1 GABRIELSSON,J . see WAKELKAMP, M effect model including endogenous ILSON,B . see TENERO, D.M GAERTNER, HJ. see SCHABER, G production, 11 ILTON, M.K. see TAYLOR, M.1 GAJDOS, P. see ANNANE, D HEFTING, N.R. see SEABER, E.} IN’T VELD, B.A. see FEENSTRA,J GALLAND, A. see BODE-BOGER, S.M. HENDRICK, D.J. see DEVEREUX, G GANDON, J.M. see PATAT, A. HENRY-MOWATT, J.S. see KEWN, S JACKSON, P.R. see OATES, A GANSER, A. see KIRCHNER, G.1 HERBEN, V.M.M., SCHELLENS, JACKSON, S.K. see ELLIS, G.R GARDINER, I. see RAMSAY, | J.H.M., TEN BOKKEL HUININK, JAEHDE, U. see SALEMING, W GERTZ, B,J. see REID, K W.W., ROSING, H., VAN JAGER, D. see BRUNNER, M GIUDICELLI, J-F. see BELLISSANT, E ZOMEREN, D.M., BEUSENBERG, JAILLON, P. see BLASCHKE, T.I GLEITER, C.H. see F.B., ROSS, G. & BEIJNEN, J.H. A JANSEN, R.W.M.M see VAN KRAAIJ, FREUDENTHALER, S new oral dosage form of topotecan DJ.W GLUE, P. see KHAKOO, S$ bioavailability and effect of food co JICK, H. see MYERS, M.W GO, L.H. see VAN KRAAJJ, DJ.W administration, 630P JODRELL, D.1. see ROSARIO, M.C GORGELS, A.P.M. see DE HICKS, A. see LUNNON, M.W JOHNSON, E:S. see WARRINGTON,S . iC h STOPPELAAR, F.M. GRIBNAU, HIGUCHL, S. see HAYASHI, N JOHNSON, M.A., VERPOOTEN, G.A., F.W J. see VAN KRAAIJ, DJ.W HILL, R.G. see LONGMORE, J] DANIEL, M.J., PLUMB, R., MOSS, J., 3-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 635 Index VAN CAESBROECK, D. & DI KINOSHITA,H . see HAYASHI, N eloxicam and piroxicam: a double BROE, M.E. Single dose KIRCHNER, G.I., FRANZKE, A., blind placebo-controlled study, 133 rmacokinetics of lamivudine in BUER,J ., BEMI.,L PR,OBS T IPWORTH, B,J. & CLARK, D.J. Early biects with impaired renal function and KEPPER, F., WITTKE, F., g absorption profile of non-CF(¢ 1¢ effect of haemodialysis, 2 OVERMANN, K., LASSMANN,S tamol via small and large volume MAT JONKERS, R.E. & KOOPMANS, R.P HOFFMANN, R., KIRCHNER, H plastic spacer devices, 45 Vv ihe pharmacokinetics and GANSER, A. & ATZPODIEN,J LIPWORTH, B,J. see KIELY, D.G Pharmacokoifn reectomibicnasnt LIU, G. see REID,K srednisolone (MP) during puls« human interleukin-2 in advanced renal LOCKE, C.S. see QUELLET, D LOFT, S. see HADERSLEV, K.\ il Carcinoma patients tolowl 1 dy in ¢ patients, 618P ibcutancous application, 5 LOHMAN, J.J.H.M. see VAN DER KUY, INKMAN, J.H.G. see SEABER, E.] KIRCHNER,H . see KIRCHNER, G.l P.-H.M JONKMAN, J.H.G. see PEETERS, P.A.M KIVISTO, K.T., KANTOLA, T. & LONGMORE, J., RAZZAQUE, Z.., IRKASKY, D.K PTENERO, D.M NEUVONEN, P_]. Different effects of SHAW, D., DAVENPORT, A.P., JOUBERT, P. & BOYD, A. How does a raconazole on the pharmacokinetics of MAGUIRE, J., PICKARD, J.D., oper vastatin and lov wattle 19 SCHOFIELD, W.N. & HILL, R.G Compoaf trhe ivasosconostrnict or KLOTZ, U. see LI, G JOVIC,R SALEMING, W ts of rizatriptan and sumatriptan in KLOTZ, U. see MORIKE, K n isolated cranial arteries KNAPP, M.]. seeF ONTANA, R.J nunohistological demonstration of KAGER, P.A SCHIPPER, H.G KNEALE, B.J., CHOWIENCZYK, P.]. & nvolvement of 5-HT),-receptors, KAMALI, I e BIRCH, D RITTER M. Actions of propranolol on noradrenalin ediat KAMALI, F. see BIRCH, D YONEN, A.J.M. see VEEN, G.] KAMINSKY, L.S. see FONTANA, R.] Océ ) oO vas ré LUGT, CH.B. see PEETERS, P.A.M KANTOLA, 1 KIVISTO, K.1 of men and women, 281P NNON, M.W., HICKS, A., HOUSI KARBWANG, J. see EZZET, | KOBAYASHI, K. see NAKAJIMA, M F., OLSP.,S PIKEO, NN., S,UMN ER Mc! KASTELEIINNOLST TRENITE, D.G.A KOOPMANS, P.P. see BURGER, D.M M.]., TAYLOR, LW. & WATTS, LS. A A mparison of lamotr KOOPMANS, P.P. see HUGEN, P.W.H rst evaluation in man of escalating Me! KOOPMANS, R. see SCHIPPER, H.G ¢ intravenous doses of glycoprotein MI of an epilepsy 626P KOOPMANS, R.P. see JONKERS, RI IIb/IIla receptor antagonist GR233548, MI KASTELEI]NNOLST TRENITE, D.G.A KOSUGE, K. see KIMURA, M 81P MI DE HAAN, G.] KRAUWINKEL, W.].]. see LUSARDI, P. see FOGARI, R KELLY, P. see BIRCH, D BURGGRAAF, ] LYPNYJ, D. see KHAKOO,S MI KENNA, J.G. see RAMSAY, | KREMER, J. see GODFREY, ¢ KENNA, J. SOMCHIT, N KUROIWA, Y NAKAJIMA, M KERBUSCH, T. see HUITEMA, A.D.R MacCALUM, H. see WILKINSONI,.B MI KERGUERIS, M.1 e PAWLOTSKY, I LA MANNA, C. see DRAGO,| MACDERMOT, J. see CHOUDHURY, KEWN, S., HOGGARD, P.G., HENRY LANG, D. see ELLIS, G.R RP MOWATT, ].S., BARRY, M.G. & LAPEYRE-MESTRE, M. see DESBOEUF, MAGGS, J.L. see PARK, B.K BACK, D.]. Enhanced activation of MAGGS, J.L. see BISHOP, L.P.D K oside analogues in the ce of LAPORTE, J.-R., VIDAL, X., MAGGS, J.L. see BOOCOCK, D.] yxyurea in vitro, 283P BALLARIN, E. & IBANEZ, L. Possibl MAGGS, J.L. see NAISBITT, D.J KHAKOO,S ., GLUE, P., GRELLIER, I MAGGS, J.L., BATTY, K.T., ILETT, K.F., ssociavion between OC ular MI WELLS,B ., BELL, A., DASH,¢ hloramphenicol and aplastic anaemia EDWARDS, G. & PARK, B.K MI MURRAY-LYON, I., LYPNYJ, D the ibsolute risk is very low, 181 Isomerization in human urine of a MI FLANNERY, B., WALTERS, K. & ASSMANN,S . see KIRCHNER, G.1 DUSHEIKO,] G). M. R}i bavirin LAYTON, G. see PECK, R.W 9n19d3opp eroxide drug dihydroartemisin, MI ron alfa b in chr AZZARI, P. see FOGARI, R MI EE, A.F.C. see KIELY, D.G MAGUIRE, J. se LONGMORE, J MI d pharmacodynamic interactions, 563 MALCOLM, J. see BAILEY, D.G LENDERINK, A.W. see VAN DEN MI KHAN, S.Q., STRACHAN, F.I MALIEPAARD, M. see MEERUM TER BEMT, P.M.L.A MI MEGSON,I .L., MAZZEI, F.A WOGT, ].M ENDERINK, A.W. see VAN ROON, NEWBY, D.E., BUTLER, A.R. & MALINGRE, M.M., MEERUM TER E.N WEBB, D.]. A comparisofo nth e effects WOGT, J.M., SCHELLENS, J.H.M LEONARD, J.M. see OQUELLET,D MI of RIG-200, a novel S-nitrosated glyco DUCHIN, K., ROSING, H. & EONE,A . see BUTLER, R Mé BEIJNEN, J.H. Co-administration of ESIEUR, O. see ANNANE,D dorsal Nand veins of healt! yclosporin A interferes with paclitaxel subiects in vivo. 280P UFKENS, H.G.M. see VAN DEN tabolism in humans, 626P Mi KIELY, D.G., LEE, A.F.« BEMT, P.M.L.A MALLARD, N. see WARRINGTON, S$ Mi STRUTHERS, A.D. & LIPWORTH WIS, M.]. see ELLIS, G.R MANN, R.D. Prescription-event B.J. Nitric oxide: an important rote mm , G., GONG, P.L., QIJ.U, ZE,NG, I 1onitoring — recent progress and future 1c Maintenance Of systemic and D. & KLOTZ, U. Stereoselective steady 1orizons, 195 pulmonary vascular tone in man, 263 state disposition and action of MANN, R.D. see MARTIN, R.M Mi KIMURA, M., UMEMURA, K.., propafenone in Chinese subjects, 441 MARINO, A. see DRAGO, I M KOSUGE, K., NISHIMOTO, M LINDNER, J. se MCMANUS, P MARINO, V. see DRAGO, I OHASHI, K. & NAKASHIMA, M LINDUP, W.E. see HALIFAX, K.I MARLEY, J. see MCMANUS, P Attenuation by ACE inhibitor drugs of LINDUP, W.E. see SHAH, LA MARTIN, D.E. see TENERO, D.M z-adrenoceptor sensitivity in human LIPSCOMB, G.R., WALLIS, N.., MARTIN, R.M., BISWAS, P.N., vessels: possible differences related to ARMSTRONG, G. & REES, W.D.W FREEMANTLE, S.N., PEARCE, G.1 drug lipophilicity, 599 Gastrointestinal tolerability of & MANN, R.D. Age and sex 636 © 1998 Biackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 Index distribution of suspected adverse drug MOSS, J. see JOHNSON, M.A OOSTELBOS, M.C.].M. see VEEN, G.] reactions to newly marketed drugs in MOUSTAFA, M. see HUSSAIN, F.N OOSTERHUIS, B. see PEETERS, P.A.M neral practice in England: analysis of MOYOU, R.S. see PEETERS, P.A.M ORLANDO, R., FLOREANI, M., 48 cohort studies, 505 MUCKLOW, J.C. A manual of adverse PADRINI, R. & PALATINI, P MATHER, L.E., WOODHOUSE, A., drug interactions (Book review), 275 Determination of inulin clearance by WARD, M.E., FARR, S.]., MUGELLINI, A. see FOGARI, R bolus intravenous injection in healthy RUBSAMEN, R.A. & MULDER, J.W. see BURGER, D.M subjects and ascitic patients: equivalenc ELTHERINGTON, L.G. Pulmonary MULDER, J.W. see HUGEN, P.W.H of systemic and renal clearances a ninistration of acrosolised fentany! MULL, R. see EZZET, I glomerular filtration markers, 605 nacokinetic analysiosf systemic MULLER, M. see BRUNNER, M ORME, M. Drugs and human lactation delivery, 37 MURRAY, G.D. The design and analysis of Book review), 91 MATHIEU, B. see ANNANE,D sequential clinical trials (Book review), OSBORNE, C.M. see PEETERS, P.A.M MAURO, K. see ADEOYIN, A $13 OTTO,C ., PARHOFER, K.G., MAZZEI, F.A. see KHAN, S.Q MURRAY, L. Sample size tables for clinical RITTER, M.M., RICHTER, W.O. & McCULLOCH, P.G. see SHAH, LA studies (Book review), 616 SCHWANDT, P. Effects of acipimox McGRATH, J.C. Use of models to study MURRAY-LYON, I. see KHAKOO, S$ on haemorpheology and plasma vascular aspects of heart failure, 360 MUSCARA, M.N. see DA SILVA, C.M.I lipoprote Ins in patients with mixed McKENNA, W.]. Genetic aspects of heart MYERS, M.W. & JICK, H. Terfenadinc hyperlipoproteinaemia, 473 failure, 36 ind 2r isrek of acutsheai ilicvetr disea» se, De2 51 OUELLET, D., HSU, A., QIANJ,. , McKILLOP,D . see WILD, M_] LOCKE, C.S., EASON, C,] McLEOD, H.L. see RIDGE, S.A NACKE, A. see REICHEL, (¢ CAVANAUGH, J.H., LEONARD McMANUS, P., MARLEY, J., BIRKETT, NAISBITT, D.J. see WILLIAMS, D.P ].M. & GRANNEMAN, G.R. Effect of D.J. & LINDNER, J., Compliance with NAISBITT, D.J., VILAR, J., WILKINS, ritonavir on the pharmacokinetics of restrictions on the subsidized use of E.G.L., BARRY, M. PIRMOHAMED, ethinyl oestradiol in healthy female proton pump inhibitors in Australia, 409 M. & PARK, B.K. Plasma cysteine volunteers, 111 ES.RA McMheUarRt RAfaiYlu,re J(.C HRFe)c ent3 60 trials in chronic diemfpilciiceantciyo nsi n foHr IVs ulipnhfaecmteetdh apzaotlieen ts OUWDEJL.SW, L.H.R. see VAN KRAAIT], McNEILL, K.L. see FONTANA,| hypersensitivity, 285P OVERMANN, K. see KIRCHNER, G.1 NAISBITT, D.J., WILLIAMS, D.P., MEENHORST, P.L. see BURGER, D.M PIRMOHAMED, M. & PARK, B.K MEENHORST, P.L. see HUGEN, P.W.H Amodiaquine-induced neutrophil PADRINI, R. see ORLANDO, R MEERUM TER WOGT, J|.M. see apoptosis, 292P PALATINI, P. se ORLANDO, R MALINGRE, M.M NAISBITT, D.J., WILLIAMS, D.P., PALMER, J.L. see DE ALWIS, D.P MEERUM TER WOGT, J.M., BEIJNEN, MAGGS, J.L., PIRMOHAMED, M. & PALMER, J.L., BARRINGTON, P. & J.H., TEN BOKKEL HUININK, PARK, B.K. Metabolism-dependent O'CONNOR-SEMMES, R. Safety W.W., ROSING, H., VAN neutrophil toxicity of amodiaquine: a tolerability and pharmacokinetics of the MEERUM TER WOGT, J.M., BEIJNEN, comparison with related antimalarial NK, receptor antagonist GR205171 in JJ.. TEN BOKKEL HUININK, W.W drugs, 291P healthy male volunteers, 298P MALIEPAARD, M., TIBBEN, M., NAKAJIMA, M., KOBAYASHI, K., PALMER, J.L., FUMOLEAU, P., WELBANK, H., GROENEWEGEN, SHIMADA, N., TOKUDOME, S., BRYSSINE, B., DIEMUNSCH, P., G. & SCHELLENS, J.H.M. Phase I and YAMAMOTO, T. & KUROIWA, Y SCHOEFFLER, P., SPRAGGS,C . & pharmacologic study of SPI-77, a new Involvement of CYP1A2 in mexiletine GRAHAM, E. Preliminary aF., liposomal encapsulated formulation of metabolism, 55 pharmacokinetcs of the NK, receptor MEGSON, LL. see KHAN, $.Q NAKASHIMA, M. see KIMURA, M antagonist GR205171 in patients with MEINEKE, I. see FREUDENTHALER, S$ NAWARATNE, S., BRIEN, J.1 chemtherapy-induced or post operative MERKUS, F.W.H.M. see VAN DER SEEMAN, E., FABINY, R., nausea and vomiting, 297P KUY, P.-H.M ZALCBERG, J., COSOLO, W.., PANFILOV,V . see UEDA, S$ MIGET, N. see PATAT, A ANGUS, P. & MORGAN, DJ PARHOFER, K.G. see OTTO, ¢ MIKUS, G. see MORIKE, K Relationships among liver and kidney PARK, B.K. see BISHOP, L.P.D MILLER, A.K. see TENERO, D.M volumes, lean body mass and drug PARK, B.K. see BOOCOCK, D.] MILLER, K. see GODFREY, ¢ clearance, 447 PARK, B.K. see GILL, H_] MINTO,C . & SCHNIDER, T. Expanding NEUVONEN, P.]. see KIVISTO, K.1 PARK, B.K. see MAGGS, J.1 clinical applications of population NEWBY, D.E. see KHAN, S.Q PARK, B.K. see NAISBITT, DJ pharmacodynamic modelling, 321 NIEMEYER, M.G. see TEN HAVE, S.M PARK, B.K. see WILLIAMS, D.P MISSO, N.L.A. see TAYLOR, MI NIMMO, W. see BARDSLEY, H PARK, B.K., O'NEILL, P.M., MAGGS MONTASTRUC, J.-L. see DESBOEUF, NISHIMOTO, M. see KIMURA, M J.L. & PIRMOHAMED, M. Safety K assessment of peroxide antimalarials MORGAN, D.]. see NAWARATNE, S$ (’CONNOR-SEMMES, R.. see clinical and chemical perspectives, 52 >1 MORIKE, K., PLATTEN, H.P., MIKUS, PALMER, J.1 PARK, B.K. see PIRMOHAMED, M G. & KLOTZ, VU. Variability in the O’KANE, K. Streetwise drugwise (Book PARK, B.K. Prediction of drug-induced future frequency of cytochrome P450—2D6 review), 615 hepatotoxicity, 357 (CYP2D6) deficiency, 87 O'NEILL, P.M. see PARK, B.K PATAT, A., TROCHERIE, S., MIGET MORRIS, A.D. see BUTLER, R O’NEILL, P.M. see BISHOP, L.P.D N., ENSLEN, M., GANDON, J.M. & MORRIS, A.D. see UEDA,S OATES, A., JACKSON, P.R., AUSTIN, ROSENZWEIG, P. Effects of a slow MORRIS, R.G., BLACK, A.B., HARRIS, C.A. & CHANNER, K:.S. A new release formulation of caffeine on EEG A.L., BATTY, A.B. & SALLUSTIO, regimen for start warfarin therapy in out pscyhomotor and cognitive functions 1n B.C. Lamotngine and therapeutic drug patients, 157 sleep-deprived health volunteers, 285P monitoring: retrospective survey OHASHI, K. see KIMURA, M PAWLOTSKY, F., THOMAS, A., following the introduction of a routine OLIVE, G. see FABRE, I KERGUERIS, M.F., DEBILLON, 7 service, 54 OLSSON, P. see LUNNON, M.W & ROZE, J.C. Constant rate infusion of 133-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 637 Index RADEMAKER, M.V. see DE HAAN, G.] ROTBLAT, F. What information does the SCH new OSA chedule, 163 RAMSAY, L., BARNES, S., GARDINER, lator presently require before SCHI PEARCE, G.L. see MARTIN, R.M I., ELIASSONE . & KENNA, J.G a new drug to be used in FI PECK, R.W. see SEABER, E.] Idenuficauion by immunopre¢ ipitatiion of patients with liver disease? 352 SCH’ PECK, R.W., WOOTTON, R., WIGGS nove! halothane-induced protem YUTLEDGE, P.A. see BRACCHI, A.D S R., LAYTON, G. & POSNER, J. Eff tigens recognized by antibodies from ROUTLEDGE, P.A. see SHETTY paticnts with halothane hepatitis, 303P H.G.M RAMSAY, L.A. see SOMCHIT, N LOUTLEDGE,R .A., SHETTY, H.G.M SCH RAPHAEL, J.¢ ee ANNANE, D WHITE, J.P. & COLLINP.S C,as e SCIB PEDRAZZOLI ee DA SILVA, C.M.1 RAWLINS, M.D. What does a doctor nc therapeutics Wartarin SEAI PEETERS, P.A.M., BEUKEMA, ] to Know about a new drug Defore It 1s stance and inefhicacy in a man with D OOSTERHUIS, B., SMEETS rrent thromboemt F.W.M., MOYOU, R-S., THIETCHI Oaggut lant—associatea pprrii apism 343 ROWKINS, S. se WARRINGTON, S F., OSBORNE, C.M., THUMA, P.I BHAT, G.]., BIEMBA, G RAZZAQUE, Z. see LONGMORE, } ROZE, J.C. see PAWLOTSKY,I SHAKANKALE, G.M., JONKMAN REES, W.D.W. see LIPSCOMBG,.R RUBSAMEN, R.A. seeM ATHER, L.I 7¢ }.H.G. & LUGT, CH.B REIBALDI, A. see DRAGO,| RUSSEL, F.G.M. see DEKKER, S SEBI REICHEL, C., SKODRA, T., NACKE, SEEN A., SPENGLER, U. & SESS SALEMING, W., JAEHDE, | SAUERBRUCH, T. The lignocaine SHA SCHONING,H . & SIEGERT, W. O tabolite (MEGX) liver function test PENG, Y SCHAEFERJ,. P thylation of etoposide: a potential ind P-450 induction in humans, 535 PETERSON, D.W. see BRADY, P.A of drug interactions, 627P REID, K., SCIBERRAS, D.G., GERTZ PHIBOONBANAKIT, D., BARRY SALEMING, W., JOVIC, R., AMREIN B.J., REINHARDT, R.R., LIU, G M.G. & BACK, D.J. Q R. & DINGEMANSE, J. Tolerability, GOLDING, |.F. & STOTT, J.R.R 1acokKinectics ana 94P Comparison of a neurokinin 1codynamics of combined PICKARD, J.D LONGMORI | 98,298, and scopo obemide and diazepam in healthy with placebo in the prevention of PICKKERS, P DE HOON, ].N.].M ts, 628P PIECHAUD, J-I FABRE, I ouon-induced nauseai n man, 282P SALLUSTIO, B.C. see MORRIS, R.G REIDENBERG, M.M. & PIEGLER, I BRUNNER, M SAPONE, A. see RIDGE, S.A PIKE, N LUNNON, M.W BRECKENRIDGE, A. Summary SAUERBRUCH, T. see REICHEL, ¢ SHA PIRMOHAMED, M. & PARK, K. Arc SCHABER, G., STEVENS,L. , SHA REIDENBURG, M. Cl GAERTNER, H,J., DIETZ, K. & SHI BREYER-PFAFF, U. Pharmacokinet PIRMOHAMED, M. see PARK, B.K REIMCHE, L. seeS CHAEFER, J.P f clozapine and its metabolites in SHI PIRMOHAMED, M. see GILL, H.J REINHARDT, R.R. see REID, K hiatric patients: plasma protein SHI PIRMOHAMED, M. see NAISBITT, D_] REY, E. see FABRE, I nding and renal clearance, 453 PIRMOHAMED, M. see WILLIAMS, D.P RICHELL, R. see TOWARD, 7 J HAEFER, J.P., TAM, Y., HASINOFF, SHI PLATTEN, H.P. see MORIKE, K RICHTER, W.O. see OTTO, ¢ B.B., TAWFIK, S., PENG, Y.., PLUMB, R.. see JOHNSON, M.A RIDGE, S.A., SLUDDEN, J., BROWN REIMCHE, L. & CAMPBELL, N.R.¢ SHI O., ROBERTSON, L., WEI, X POGGI, I ¢ SPEIRS, C.J I ous sulfate interacts with captopril, SAPONE, A., FERNANDEZ POLIMENON,. C. see DA SILVA, C.M.1 PONS, G. see FABRE, |} SALGUERO, P.M., GONZALEZ, F.} SCHARER,K . see PORT, R.I VREKEN, P., VAN KUILENBURG SCHEININ, H. see WAKELKAMP, M OOLE-WILSON, P. Fi A.B.P., VAN GENNIP, A.H. & SCHELLENS, }.H.M. see HER BEN, SHI McLEOD, H.L. Dihydropyrimidine V.M.M SHY PORT, R.E., DING, R.W., FIES, T. & hydrogenase pharmacogenctics 1n SCHELLENS, J.H.M. see MALINGRE, SIEC SCHARER, K. Predicting the (Caucasiat pa 15 M.M SIE] AILEY, S.A. see HUSSAIN, F.N SCHELLENS, ].H.M. see MEERUM TER SIM LITTER, J.M. see BRETT, S.I WOGT, J.M ina 1, 46 LITTER, J.M. see FONTANA, I 7, HIPPER, H.G., BUTTER, J.]., SK¢ POSNER, J. see PECK, R.W RITTER, J.M. see KNEALE, B.] KAGER, P.A., VAN BOXTEL, C_]. & SLL POULSEN, H.1 e HADERSLEVK,.\ LITTER, M.M. see OTTO,¢ KOOPMANS, R. The effect of SM/ PROBST-KEPPER, M. see KIRCHNER LOBERTS, M.S. see CROSS, S.I 1etidine and dose increase on SMI G.I ROBERTSON,L . see RIDGE, S.A oncentrofa altbeindoaznol e-sulphoxide SMI PROFIT, L., BROOKS, B., WILLIAMS LODENHUIS, S. see HUITEMA, A.D.R iealthy subjects, 618P SMI D.P. & BACK, D.J. Modulation of P LOLFE, L. seeW ARRINGTON, S$ SCHMID, R. see BRUNNER, M rycoprotein function in humiat ROOTS, |. see PUCHLER,K SCHMIEDBERGER, A. see BRUNNER, SMI peripheral mononuclear cells by LOSARIO, M.C., THOMSON, A.H M SMI saq . , r 295! ) JODRELL, D.1., SHARP, C.A. & SCHNIDER, T. see MINTO,¢ SM’ PUCHLER, K., SIEERAKOWSKI, B. & ELLIOTT, H.L. Population SCHOEFFLER, P. see PALMER, J.1 ROOTS, I. Single dose and steady stat« phar 1acoking tics of gentamicin 1n S CHOEMAKER, H.C. see SOI pharmacokineticos f temocapril and patients with cancer, 229 BURGGRAAF, ] SO! temocaprilat in young and elderly ROSENZWEIG, P. see PATAT,A SCHOFIELD, W.N. see LONGMORE, J hypertensiv patients, 363 ROSING,H . see HER BEN, V.M.M Lr CHOLZE, J. & STAPFF, M. Start of PYM, A.S. see CHURCHILL, D.R ROSING, H. see MALINGRE, M.M herapy with the angiotensin II ROSING, H. see MEERUM TER itagonist losartan after immediate QIAN, J. see OUELLET, D WOGT, J.M switch from pretreatment with an ACI QIU, J. see LI, G ROSS,G . see HERBEN, V.M.M hibitor. 169 638 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 Index SCHONING,H . see SALEMING,W SONNE, J. see HADERSLEV, K.V TENERO, D.M., MARTIN, D.E., SCHREEB, K.-H. see SOUSA, S.S. see DA SILVA, C.M.I MILLER, A.K., ILSON, B., BOIKE, FREUDENTHALER,S SPEIRS, C.J., WAGNIART, F., POGGI, S.C., ZARIFFA, N. & JORKASKY, Ss CHWAGMEIER, R., ALINCIC, S. & L. Perindopril postmarketing D.K. Effect of age and gender on the STRIEBEL, H.W. Midazolam surveillance: a twelve-month study in 47 pharmacokinetics of eprosartan, 267 pharmacokinetics following intravenous 351 hypertensive patients, 63 rER BERG, J.W.M. see VAN DER KUY, and buccal administration, 203 SPENCE, J.D. see BAILEY, D.G P.-H.M SCHWANDT,P . see OTTO,( ¢ SPENGLER,U . see REICHEL, ¢ THIETCHE, F. see PEETERS, P.A.M Sy CIBERRAS, D.G. see REID,K SPRAGGS,C . see PALMER, J.1 THOMAS, A. see PAWLOTSKY, SEABER,E .]., PECK, R.W., SMITH, STANKE,F ., DEVILLIER,P , BREANT, THOMPSON, PJ. see TAYLOR, M.1 D.A., ALLANJ.S, OHEFNTI,NG , D., CHEVANON, O., SESSA, (¢ THOMSON, A.H. see ROSARIO, M.¢ N.R., VAN LIER, J.J., SOLLIE, F.A.E., BRICCA, G. & BESSARD, G THUMA, P.E. see PEETERS, P.A.M WEMER, J. & JONKMAN, J.H.G Frusemide inhibits angiotensin II rIBBEN, M. se MEERUM TER WOGT, The absolute bioavail lit and effect of induced contraction on human vascular J.M rIBBEN, M.M. see HUITEMA, A.D.R rood on the pnar macoKkIine smooth muscle, 571 zolmitriptan in healthy volunteers, 433 STAPFF, M. see SCHOLZE,J TINER, R. see DOYLE, K SEBILLE,V . see ANNANE,D STAPPERS, ].L.M. see DI TINGLE, M.D. see GILL, H.] SEEMAN,E . seeN AWARATNE, S STOPPELAAR, F.M PFOKUDOME, S. see NAKAJIMA, M SESSA,C . see STANKE, | STEEDS, R.P. & CHANNER, K.S TOLL, P.J.M.M. see VEEN, G.] SHAH,I .A., LINDUP, W.E. & POWARD, T., RICHELL, R., GREWAL, Recent advances in the management of McCULLOCH, P.G. Freundlich and unstable angina and non-Q-wave H.K., BYE, C. & BABER, N Langmuir isot} herms as descriptors of myocardial infarction, 335 Applanation tonometry: reproducibility inC adsorptiotno acti STEEGERS, E.A.P. see DEKKER,S and repeatability of pulse wave forms and charcoal, 299P STEVENS, I. see SCHABER, G pulse wave velocity using the SHAH,I .A., LINDUP, W.E. & sphygmocor system, 286P STOLK, L.M.L. see DE STOPPELAAR, McCULLOCH, P.G. The effect of POWARD, T., RICHELL,R ., GREWAL, F.M proteoni tnh e adsorptioonf mitomycin H.K., BYE, C. & BABER, N STOTT, DJ. Drug therapy in old age C to activated charcoal, 300P Applanation tonometry: variation in Book review), 413 SHAKANKALE, G.M. see PEETERS, pulse wave forms as a result of STOTT, J.R.R. see REID, K P.A.M sumulation, 287P SHARP, C.A. see ROSARIO, M.¢ STRACHAN, F.E. see KHAN, S.Q PROCHERIE,S . see PATAT, A SHAW, D. see LONGMORE, ] STRICKER, B.H.CH. see FEENSTRA,J PSIKAS, D. see BODE-BOGER, S.M SHENFIELD, G.M. Drug development for STRIEBEL, H.W. see SCHWAGMEIER, FUCKER, G.T. Alteration of drug R women (Book review), 521 aisposiuon 1n live! impairment, 9D5 STRUTHERS, A.D. see BUTLER,R SHENFIELD, G.M. see HOSKINS, ].M STRUTHERS, A.D. see KIELY, D.G UEDA, S., DONNELLY,R ., PANFILOV SHENFIELD, G.M. Therapeutic drug STRUTHERS, A.D. see YEE, K.M V., MORRIS, A.D. & ELLIOTT, H.1 monitoring beyond 2000, 93 SUMNER, M.,]. see LUNNON, M.W Lacidipine: effects on vascular pressor rr, SHETTY, H.G.M. see ROUTLEDGE, SWART, M. see MEERUM TER WOGT, responses throughout the dosage interval R.A }.M in normotensive subjects, 127 SHETTY, H.G.M.,B USS, D.« SWEENEY, K. see GODFREY, ( UMEMURA, K. see KIMURA, M HARRY,F ., HUTCHINGS, A.D. & ROUTLEDGE, P.A. The effect of oral rAM, Y. see SCHAEFER, J.P VACHHARAJANI, N.N., SHYU, W.¢ cholestyramine on the pharmacokinetics PANG, B.K. see FONTANA, RJ SMITH, R.A. & GREENE, D.S. The of warfarin enantiomers, 290P effects of age and gender on the SHIMADA, N. see NAKAJIMA, M PASCO, F. see BILLAUD, E.M pharmacokinetics of irbesartan, 612 SHYU, W.C. see VACHHARAJANI, N.N TAWFIK, S. see SCHAEFER, J.P VAN AGTMAEL, M.A., GUPTA, V. & SIEGERT, W. see SALEMING, W PAYLOR, LW. see LUNNON, M.W PTAYLOR, M.L., ILTON, M.K., MISSO, VAN BOXTEL, C.J. Grapefruit juice SIERAKOWSKI, B. see PUCHLER, K increases the bioavailability of TER SIMONS, K.A. see VAN DEN BEMT, N.L.A., WATKID.NN.,S HU,NG, J. & artemether, 629P P.M.L.A THOMPSON, P.J. The effect of aspirin VAN BORTEL, L.M.A.B. see DE HOON, SKODRA, T. see REICHEL, ¢ on thrombin stimulated platelet adhesion j.N.J.M SLUDDEN,,J . see RIDGE, S.A receptor expression and the role of VAN BOXTEL, C.]. see SCHIPPER, H.G SMAIL, S.A. see BRACCHI, A.D neutrophils, 139 VAN BOXTEL, C.J. see VAN AGTMAEL, SMEETS, F.W.M. see PEETERS, P.A.M LLINGEN, O., SWARTM,. , M.A yx1de SMITH, D.A. see SEABER, E.] DUCHIN, K. & SCHELLENS, ].H.M VAN CAESBROECK, D. see JOHNSON, SMITH, R.A. see VACHHARAJANI, Co-administration of cyclosporin A M.A N.N CsA) enables oral therapy with VAN DEN BEMT, P.M.L.A., EGBERTS, IER, SMITS, P. see DE HOON, J.N.J.M paclitaxel, 624P A.C.G., LENDERINK, A.W., SMITS, P. see DEKKER, S N BOKKEL HUININK, W.W. see VERZIJL, J.M., SIMONS, K.A., VAN SMYTH, A. The paediatric lung (Book HERBEN, V.M.M DER POL, W.S.C.J.M. & LEUFKENS, review), 615 N BOKKEL HUININK, W.W. see H.G.M. Reporting of adverse drug SOLLIE, F.A.E. see SEABER, E,] MEERUM TER WOGT, J.M reactions in hospital 1 comparison of SOMCHIT, N., RAMSAY, L.A., N HAVE, S.M., CLEOPHAS, T.]., doctors, nurses and patients as sources of KENNA, J.G. & CALDWELL,J HOL, C.W., VAN DER MEULEN, J., reports, 619P Glucuronidation mediates hepatic NIEMEYER, M.G. & DE PLANQUE, VAN DEN BERG, P.B. see VAN DIJK, protein adduct formation from B.A. A randomized placebo-controlled K.N diclofenac, but not ibuprofen, in rats: a study of loop-diuretics in patients with VAN DER KUY, P.-H.M., LOHMAN, ACI potential mechanism of hepatotoxicity, essential hypertension, the BUFUI JJ.H.M., HOOYMANS, P.M., TER 304P clinical study report, 628P BERG, ].W.M. & MERKUS, 33-640 © 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 633-640 639 Index F.W.H.M. Pharmacokineticosf VAN THOOR, C.]. see WILKINSON, WEMER,, J. see SEABER, E.J 1.B WHITE, I.N.H. see BOOCOCK, D.] ihydroergotamine, 623P VAN ZOMEREND.,M . see HERBEN WHITE, J.P. see ROUTLEDGE, R.A VAN DER LINDEP.ND., s ee V.M.M WHITE, M. see BIRCH, D FEENSTRA, | VAUZELLE-KERVROEDAN, F. see WIGGS, R. see PECK, R.W VAN DER MEULEN, J. see TEN HAVI FABRE,I WILD, M.J., BUTTERS, C.J]. & a-adr S.M VEEN, G.]., OOSTELBOS, M.C.].M., McKILLOP, D. Determination of the a-hy VAN DER MEULEN, J., VAN DER TOLL, P.J.M.M. & LOONEN, A.J.M hepatic cytochrome P450 ACI SLUIJS, J.P., CLEOPHAT.S],. & Effect of blood collection tubes o1 Zymes INnvoi. ved . in ZOi. mitriptan ana ACI ZWINDERMAN, A.H. Replacemen ricyclic antidepressantb lood levels \-desmethy! zolmitriptan metabolism i All ACE-inhibitors by All-receptor 631P 29QP 7 VERME]], T.A.C. see EDELBROEK, WILKINS, E.G.L. see NAISBITT, D.] Acet P.M WILKINSON, I.B., HUPPERETZ, P.¢ Adar 11a ) ( ell ictaboh VERPOOTEN, G.A. see JOHNSON VAN THOOR, C.J., MacCALUM, H Adre VAN DER POL, W.S.C.J.M. see VAN M.A COCKCROFPT, J.R. & WEBB, D_J Adve DEN BEMT, P.M.L.A VERZIJL, ].M. see VAN DEN BEMT A 1yperglycaemia reduces central Advi VAN DER SLUIJS, J.P VAN DER P.M.L.A terial pressure in healthy subjects, 289P Advi MEULEN, ] VERZIJL, J.M. seeV AN ROON, E.N WILKS, M. see BRADY, P.A A fric VAN DIJK, K.N., DE VRIES, C.S., VAN VIDAL, X. see LAPORTE, J.-R WILLIAMS, D.P. see PROFIT, | Age. DEN BERG, P.B., DIIKEMA, A.M VILAR,J . see NAISBITT, D.] WILLIAMS, D.P. see NAISBITT, D_J Agre BROUWERS, J.R.B.J. & DE JONG VREKEN, P. see RIDGE, S.A WILLIAMS, D.P., NAISBITT, DJ Airv PIRMOHAMED, M. & PARK, B.K Albe VAN DEN BERG, L.T.W WAGNIART, F., see SPEIRS, C.J Co! WAKELKAMP, M., ALVAN, G., Clozapine induces tinoenu-tdreoppheinld enatp optosis AAllzcl« SCHEININ, H. & GABRIELSSON, J] Lys: implicatiofnosr Aml The influence of dr nt y rh VAN GENNIP, A.H. see RIDGE, S.A ¢ ulocytosis, 282P VAN HAARST, A.D. see BURGGRAAF, } WILLIAMS, K.M. see CAMPBELL, T.] Ana WILTSHIRE, H.R. see HALIFAX, K.I Ang VAN KRAAIJ, D.J.W., JANSEN WALLIS, N. see LIPSCOMB, G.R R.W.M.M, GO, I.H., BOUWELS WALTERS, K. see KHAKOO, $ WITTKE, F. see KIRCHNER, G.I Ang WOODHOUSE, A. see MATHER, L.I Ang L.H.R., HOEFNAGELS, W.H.1I WARD, ME. seeM ATHERL,. I WOODS, F.]. see BRACCHI, A.D Ang GRIBNAU, F.W,]. A rando1 WARRINGTON, S., BOYCE, M WOOLF, T.F. see FONTANA, R.] Ang oO ROLFE, L., CLARKE, A WOOLLARD, G.A. see MALLARD, N. & JOHNSON, E.S ANDERSON, B.] Ant Higher availability elegil WOOTTON, R. see PECK, R.W Ant VAN KRAAIJ], DJ.W., JANSEN Zydis™ thar Deprenyl™ for n WOUTERSE, A.C. see DEKKER, S Ant R.W.M.M., BOUWELS, L.H.R. & HOEFNAGELS, W.H.L. Post ssor response to oral tyramin WRIGHTD,. J. see AL-RASHED, S.A Ant »84P WRIGHT, D.J., AYKROYD, R.G. & Ant Od pr re reductions 1n eciderly CHRYSTYN H. Rating clinical Ant WARRINGTON, S., BOYCE, M., ROLFE, L., CLARKE, A nacy interventionbsy clinical Ant MALLARD, N., ROWKINS, S. & s: which health professionals should An vith Ww 625P led?, 27 Ap! VAN KRAAI], DJ.W., JANSEN JOHNSON, E:S. Are the metaboliteosf ded?, 278P Ap R.W.M.M., DE GIER, J.J Art GRIBNAU, F.&W H.OEFJNA.GEL S AMAMOTO, T. see NAKAJIMA,M W.H.L. Prescription patteorfn dsiu t yra , 297P YEE, K.M. & STRUTHERS, A.D Art Lx } ommunity-awe WATKINS, D.N. see TAYLOR, M.1 Endogenous angiotensin II and Ast atients, 403 WATKINS, P.B. see FONTANA, R.] roreceptor dysfunction: a comparative Ast VAN KUILENBURG, A.B.P WATSON,N . see BARDSLEY,H dy of losartan and enalapril in man, At RIDGE, S.A WATTS, LS. seeL UNNON, M.W VAN LIER, J.}. seeS EABERE,. ] WEBB, D.]. see KHAN, S.Q YUKAWA, E. see HAYASHI, N VAN ROON, E.N., EGBERTS, A.C.G WEBB, D.]. see WILKINSON, 1.B VERZIJL, J.M. & LENDERINK, A.W WEBER, J.N. see CHURCHILL, D.R Ba Patterns of switching and stopping init WEI, X. see RIDGE, S.A ZALCBERG, J. see NAWARATNE,S $ Be ZARIFFA, N. see TENERO, D.M WEIR, N.W. see HUSSAIN, F.N Be HAART) in a cohofo Durtcht HI V WELBANK, H. see MEERUM TER ZENG, F.-D. see LI, G Bi sCTOpOSIO VC patients, 62 P WOGT, ].M ZOPPI, A. see FOGARI,R Bi VAN TELLINGEN, O. see MEERUM WELLER,C . see BRADY, P.A ZWINDERMAN, A.H. see VAN DER Bl TER WOGT, J.M WELLS,B . see KHAKOO,S MEULEN, J Bl Bc Be Be Bc Be Be Be 640 © 1998 Blackwell Science Ltd Br| Clin Pharmacol, 45, 633-640 SUBJECT INDEX his index was compiled from the keywords x-adrenoc eptor, 599 Book review: Streetwise Drugwise—a Drug cocktail, 2-hydroxytamoxif layman’s guide 615 Drug developer, 352 ACE inhibitor, 363 Book review: The design and analysis of Drug development, 351 ACE inhibitors, 630P sequential 413 Drug disposition, 355 All receptor antagonists, 630P Book review: The paediatric lun Drug input rate, 479 Acetominophen, 237 Buccal, 203 Drug interaction, 1, 101, 111, 377, 563 Acetylcholine, 51 BUFUL clinical study, 628P Drug interactions, 627P Adaptation, 133 Bufuralol, 55, 295P Drug metabolism, 151 Adrenal function, 589 Drug regulator, 352 Adverse drug reaction monitoring, 63 ~ >YP2C19, 499 Drug safety monitoring, 195 Adverse drug reactions, 279P, 505, 619P CYP2D6, 55, 295P Drug utilization, 409 9p Adverse effects, 255 CYP3A4, 101, 535 Drug-induced hepatotoxicity, 357 African children, 629P Caffeine, 221, 285P Drugs and the liver, 351 267, 505, 612 Calcitonin gene related peptide, 621P Duration of action, 12 Agranulocytosis, 282P Calcium antagonists, 58 Airway responsi “ness, /9 Cancer, 229 Efffeecctt comNpnaarrttmmeenntt <7 27 x yw Albendazole-sulphoxide, 618P ( uptopril, 169, 377 Elderly, 363, 531, 625P Alcohol, 278P, 301P Cardiac catheterisation, 395 Enalapril 583 Alzheimer’s disease, 221 Cardiovascular function, 245 Enantuiomers, 79, 290P, 441, 627P Ambulatory blood pressure monitoring, 169 cDNA expressed microsomes, 55 Endogenous production, 11 Amodiaquine, 292P Central arterial pressure, 289P Endothelial function, 279P, 51° Analysis, 547 Cerebrospinal fluid, 237 Endothelium, 489 Angiotensin, 599 Charcoal, activated, 299P, 300P Epilepsy, 547, 626P Angiotensin II, 571, 583 Chloramphenicol, 181 Epoctin B, 11 Angiotensin II receptor antagonist, 267 Chloroquine, 215 Eprosartan, 267 Angiotensin antagonism, 169 Cholestyramine, 290P Erythropoictin, 11 Angiotensin converting enzyme inhibitor, Cimetidine, 618P Ethinyloestradiol, 599 Cisplatin, 625P Ethoxyresorufin 55 Anti-epileptic drugs, 185 Clinical Pharmacology studies, 347 Etoposide, 627P Antiarrhythmic drugs, 307 Clinical interpretation, 95 Exercise blood pressure, 288P Anticoagulation, 157 Clinical panels, 278P Anticonvulsant, 547 Clinical pharmacy, 278P, 415 Fentanyl, 37 Antihistamines, 251 Clinical trials, 147 Fibrinogen, 473 Antimalarial, 293P Clozapine, 282P, 453 1orourach, a| Antipyrine clearance, 44 Clozapine-N-oxide, 453 Fluvastatin, 49 Antiretroviral therapy, 621P Cognitive function, Food. 83. $33. 630 Aplastic anaemia Complex formation, 377 Forearm vasculaature, 281P Applanation tonometry, 286P, 287P Compliance, 620P Freundlich isotherm, 299P Arteflene, 293P Compliance with subsidy restrictions, 409 Frusemide, 479, 571, 624P, 625P Artemether, 553, 629P Computer simulations, 321 Furafylline, 55 Artemisinin, 521 Concentration-effect modelling, 383 Aspirin, 139 Conjunctival instillation, 272 GPIlb-IIla, 139 uve Asthma, 79 Constipation, 255 GR205171, 297P Atrial fibrillation, 15 Continuous rate infusion, 163 GR233548, 281P Covariate analysis, 117 Gastrointestinal haemorrhage, 88 Creatinine clearance, 447 Gender, 83, 267, 505, 612 4-arteether, 629P Cyclophosphamide, 619P Gene-dose effect, 499 Baroreceptor, 583 Cyc losporin A, 624P, 626P General practice, 505 Beclomethasone, 207 Cysteine deficiency, 285P General pracutuioners, 279, 300P Benflumeto, 553 Cytochrome P450, 55, 176, 221, 290P, 535 Genetic aspects, 361 Bias, 147 Cytochrome P450—2D6 87 Genotype, 499 Bioavailability, 37, 433, 553, 629P, 630P Gentamicin, 229 Blood collection tubes, 631P Delayed release mesalazine, 173 Glucuronidation, 111 Blood donors, 176 Deprenyl, 284P Glycoprotein IIb/IIIa receptor antagonist, Bolus i.v. injection, 605 Diabetes mellitus, type II, 630P 281P Book review: A ma ual of adverse drug Diazepam, 628P Glycosalicylate, 29 interactions, 275 Diclofenac, 304P GR205171, 298P Book review: Drug therapy in old age, 413 Didanosine, 283P Grapefruit juice, 101, 629P Book review: Drug development for Dihydroartemesinin, 293P women 520 Dihydroergotamine, 623P HCV-RNA, 563 Book review: Drugs and human lactation 91 Dihydropyrimidine, 151 HIV infected patients, 285P, 620P Book review: Medical pharmacology at a Dihydropyrimidine dehydrogenase, 1, 151 HIV positive patients, 621P glanc e 91 Discharge information, 300P HIV protease inhibitors, 291P Book review: Sample size tables for clinical Diuretics, 403 HIV-1 infection, 518 trials 616 Dose-response curve, 589 HIV-protease inhibitors, 295P 3-640 © 1998 Blackwell Science Ltd 641 Percutaneous, 29 Perindopr}i l, 63 Loop diuretics P 628 Pernpheral resistance, 489 Hand vein 280P LLoosvaarstt atin1,, 1694,9 467. 583 PPe roxideaeb le anstuimpaelraorixaildse. d5i2s1m utase, 288P Low dos¢ MEGxX test, 535 P 1 icodynamics. 101, 23 321, 441 LLuonwg Iclisvietryy , lip4o5p rotein, 288P Pp o+e79p,i de56m3i.o l2o9g9y,, 62129P5, 628P ibrosis, 618P , ogenct > , KINCuCs, 5, 21, 37, 49. 83. 101 63, 203, 271. 93 26 2 290P 17P, 298P. 363, 433, 441. 541 63 Meloxicam. 133 , ‘ ) O¢ vig&iPl anc6e2, 2P, 16952 3P 6? Pp 628P H lent drug deliven 13 p 33 Metabolix Msk factors, 288P rotein binding, 291P. 453 Pp 39 P. orphisr 15 - , 69. on5 53 netics, 11, 11 , 229, ndial blood pressure, 625P P rkecting surveillance6,3 . 505 P umpsia, 622P AAwW itaA NA DpI re infants, 163 P puon sequence analysis. 255 Pr nbing, 531 Py; pOuNon peavtetnetr nsm on4i0t3o ring. 195 905 Motion sickness. 282P Pressor re sponse, 297P , 345 > care, 415 tomvcir IQQp Pric icrapy. 409 Pri iil. 499 N -< nhetyiclozepine,. 453 Pro; fenone, 441 NONMEM 16 Pp, DT nolol, 281P Py ise inhibitors, 111.518 Prot 300P p*r oton catiponu mabopia a si,n hi1b4i 14t ors. 409 Pulmonary 1dmunistration, 3 P onary circulation. 263 lors 19 3p co TO + () S99 ( oO +9 2 00, 280P ) oO Octo R vacaine 245 K oO 14 i ferences 441 i 1, Ki ous id 7 OPA/n-acetyl-] V 627P ‘ Carance, 453 nun 8 Ren 1 pu x01P R function, 21 2"5 Onpoadeny y tasc 965 R Ethics( ¢ ommiuttees, 34 ) eprazok ) I< Odialysis, 88 Ondansetro R itoid arthritis, 369 ion 624P OOrxaild atciovnet rascterpestsi v: 279P | RIRi fa \ ci1n,, 56533 5 Risk factors, 71 P glycoprotein, 295P Rautonay ] P-selectin, 139 PK PD modelling, 383 S(-) enantiome2r4,5 Paclitaxel 624P, 626P SPI ¢ 25P Paracetamol, 237 $25,513 Safety, 298P Parkinsonism 302P Safety assessment. 521 Salbutamol. 45 1998 Blackwell Science Ltd BrJ Clin Pharmacol, 45, 64/ 643 © 1998

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users